U.S. patent application number 13/857658 was filed with the patent office on 2014-02-13 for compounds useful as inhibitors of atr kinaseand combination therapies thereof.
This patent application is currently assigned to Vertex Pharmaceuticals Incorporated. The applicant listed for this patent is Vertex Pharmaceuticals Incorporated. Invention is credited to Mohammed Asmal, John Robert Pollard, Philip Michael Reaper.
Application Number | 20140044802 13/857658 |
Document ID | / |
Family ID | 48614105 |
Filed Date | 2014-02-13 |
United States Patent
Application |
20140044802 |
Kind Code |
A1 |
Pollard; John Robert ; et
al. |
February 13, 2014 |
COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASEAND COMBINATION
THERAPIES THEREOF
Abstract
The present invention relates to compounds useful as inhibitors
of ATR protein kinase and combination therapies thereof. The
invention also relates to pharmaceutically acceptable compositions
comprising the compounds of this invention; methods of treating of
various diseases, disorders, and conditions using the compounds of
this invention; processes for preparing the compounds of this
invention; intermediates for the preparation of the compounds of
this invention; and methods of using the compounds in in vitro
applications, such as the study of kinases in biological and
pathological phenomena; the study of intracellular signal
transduction pathways mediated by such kinases; and the comparative
evaluation of new kinase inhibitors. The compounds of this
invention have formula I: ##STR00001## wherein the variables are as
defined herein.
Inventors: |
Pollard; John Robert;
(Abingdon, GB) ; Reaper; Philip Michael;
(Abingdon, GB) ; Asmal; Mohammed; (Newton,
MA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Vertex Pharmaceuticals Incorporated; |
|
|
US |
|
|
Assignee: |
Vertex Pharmaceuticals
Incorporated
Cambridge
MA
|
Family ID: |
48614105 |
Appl. No.: |
13/857658 |
Filed: |
April 5, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
61620717 |
Apr 5, 2012 |
|
|
|
Current U.S.
Class: |
424/649 ;
514/212.06; 514/255.05; 514/255.06 |
Current CPC
Class: |
A61K 45/06 20130101;
A61K 31/55 20130101; A61P 17/02 20180101; A61K 31/497 20130101;
A61K 31/4965 20130101; A61K 31/496 20130101; C07D 413/04 20130101;
A61P 43/00 20180101; A61P 17/06 20180101; A61P 35/00 20180101; A61K
33/24 20130101 |
Class at
Publication: |
424/649 ;
514/255.06; 514/255.05; 514/212.06 |
International
Class: |
A61K 31/497 20060101
A61K031/497; C07D 241/28 20060101 C07D241/28; C07D 413/04 20060101
C07D413/04; A61K 33/24 20060101 A61K033/24; A61K 45/06 20060101
A61K045/06; A61K 31/4965 20060101 A61K031/4965; A61K 31/55 20060101
A61K031/55 |
Claims
1. A method of treating cancer in a patient comprising
administering a compound of Formula I; ##STR00033## or a
pharmaceutically acceptable salt thereof, wherein R.sup.1 is a 5-6
membered monocyclic aryl or heteroaryl ring having 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur, wherein
said monocyclic aryl or heteroaryl ring is optionally fused to
another ring to form an 8-10 membered bicyclic aryl or heteroaryl
ring having 0-6 heteroatoms independently selected from nitrogen,
oxygen, or sulfur; each R.sup.1 is optionally substituted with 1-5
J.sup.1 groups; R.sup.2 is a 5-6 membered monocyclic aryl or
heteroaryl ring having 0-3 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, wherein said monocyclic aryl or
heteroaryl ring is optionally fused to another ring to form an 8-10
membered bicyclic aryl or heteroaryl ring having 0-4 heteroatoms
independently selected from nitrogen, oxygen, or sulfur; each
R.sup.2 is optionally substituted with 1-5 J.sup.2 groups; L is
--C(O)NH-- or --C(O)N(C.sub.1-6alkyl)-; n is 0 or 1; Each J.sup.1
and J.sup.2 is independently halo, --CN, --NO.sub.2, --V.sup.1--R,
or --(V.sup.2).sub.m-Q; V.sup.1 is a C.sub.1-10aliphatic chain
wherein 0-3 methylene units are optionally and independently
replaced with O, NR'', S, C(O), S(O), or S(O).sub.2; V.sup.1 is
optionally substituted with 1-6 occurrences of J.sup.V1; V.sup.2 is
a C.sub.1-10aliphatic chain wherein 0-3 methylene units are
optionally and independently replaced with O, NR'', S, C(O), S(O),
or S(O).sub.2; V.sup.2 is optionally substituted with 1-6
occurrences of J.sup.V2; m is 0 or 1; Q is a 3-8 membered saturated
or unsaturated monocyclic ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur, or a 9-10 membered
saturated or unsaturated bicyclic ring having 0-6 heteroatoms
independently selected from nitrogen, oxygen, or sulfur; each Q is
optionally substituted with 0-5 J.sup.Q; each J.sup.V1 or J.sup.V2
is independently halogen, CN, NH.sub.2, NO.sub.2,
C.sub.1-4aliphatic, NH(C.sub.1-4aliphatic),
N(C.sub.1-4aliphatic).sub.2, OH, O(C.sub.1-4aliphatic), CO.sub.2H,
CO.sub.2(C.sub.1-4aliphatic), C(O)NH.sub.2,
C(O)NH(C.sub.1-4aliphatic), C(O)N(C.sub.1-4aliphatic).sub.2,
NHCO(C.sub.1-4aliphatic),
N(C.sub.1-4aliphatic)CO(C.sub.1-4aliphatic),
SO.sub.2(C.sub.1-4aliphatic), NHSO.sub.2(C.sub.1-4aliphatic), or
N(C.sub.1-4aliphatic)SO.sub.2(C.sub.1-4aliphatic), wherein said
C.sub.1-4aliphatic is optionally substituted with halo; R is H or
C.sub.1-6aliphatic wherein said C.sub.1-6aliphatic is optionally
substituted with 1-4 occurrences of NH.sub.2,
NH(C.sub.1-4aliphatic), N(C.sub.1-4aliphatic).sub.2, halogen,
C.sub.1-4aliphatic, OH, O(C.sub.1-4aliphatic), NO.sub.2, CN,
CO.sub.2H, CO.sub.2(C.sub.1-4aliphatic), CO(C.sub.1-4aliphatic),
O(haloC.sub.1-4aliphatic), or haloC.sub.1-4aliphatic; each J.sup.Q
is independently halo, oxo, CN, NO.sub.2, X--R, or
--(X).sub.p-Q.sup.4; p is 0 or 1; X is C.sub.1-10aliphatic; wherein
1-3 methylene units of said C.sub.1-6aliphatic are optionally
replaced with --NR, --O--, --S--, C(O), S(O).sub.2, or S(O);
wherein X is optionally and independently substituted with 1-4
occurrences of NH.sub.2, NH(C.sub.1-4aliphatic),
N(C.sub.1-4aliphatic).sub.2, halogen, C.sub.1-4aliphatic, OH,
O(C.sub.1-4aliphatic), NO.sub.2, CN, CO(C.sub.1-4aliphatic),
CO.sub.2H, CO.sub.2(C.sub.1-4aliphatic), C(O)NH.sub.2,
C(O)NH(C.sub.1-4aliphatic), C(O)N(C.sub.1-4aliphatic).sub.2,
SO(C.sub.1-4aliphatic), SO.sub.2(C.sub.1-4aliphatic),
SO.sub.2NH(C.sub.1-4aliphatic),
SO.sub.2N(C.sub.1-4aliphatic).sub.2, NHC(O)(C.sub.1-4aliphatic),
N(C.sub.1-4aliphatic)C(O)(C.sub.1-4aliphatic), wherein said
C.sub.1-4aliphatic is optionally substituted with 1-3 occurrences
of halo; Q.sup.4 is a 3-8 membered saturated or unsaturated
monocyclic ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or a 8-10 membered saturated or
unsaturated bicyclic ring having 0-6 heteroatoms independently
selected from nitrogen, oxygen, or sulfur; each Q.sup.4 is
optionally substituted with 1-5 J.sup.Q4; J.sup.Q4 is halo, CN, or
C.sub.1-4alkyl wherein up to 2 methylene units are optionally
replaced with O, NR*, S, C(O), S(O), or S(O).sub.2; R is H or
C.sub.1-4alkyl wherein said C.sub.1-4alkyl is optionally
substituted with 1-4 halo; R', R'', and R* are each independently
H, C.sub.1-4alkyl, or is absent; wherein said C.sub.1-4alkyl is
optionally substituted with 1-4 halo; wherein the cancer has one or
more defects in the ATM signaling pathway and/or base excision
repair.
2-7. (canceled)
8. A method of treating cancer in a patient comprising
administering to the patient a compound of Formula I; ##STR00034##
or a pharmaceutically acceptable salt thereof, wherein the
variables are as defined in claim 1; and an additional therapeutic
agent, wherein said additional therapeutic agent inhibits or
modulates a base excision repair protein.
9-11. (canceled)
12. The method of claim 8, wherein said agent is selected from
Olaparib (also known as AZD2281 or KU-0059436), Iniparib (also
known as BSI-201 or SAR240550), Veliparib (also known as ABT-888),
Rucaparib (also known as PF-01367338), CEP-9722, INO-1001, MK-4827,
E7016, BMN673, or AZD2461.
13. (canceled)
14. The method of claim 1 or claim 8, further comprising
administering to the patient an additional therapeutic agent
selected from a DNA-damaging agent; wherein said additional
therapeutic agent is appropriate for the disease being treated; and
said additional therapeutic agent is administered together with
said compound as a single dosage form or separately from said
compound as part of a multiple dosage form.
15-30. (canceled)
31. The method of claim 1, wherein said cancer is a solid tumor
selected from the following cancers: oral, lung, gastrointestinal:
genitourinary tract, liver, bone, nervous system, gynecological,
skin, thyroid gland, or adrenal gland.
32-35. (canceled)
36. The method of claim 1, wherein the additional therapeutic agent
is gemcitabine and cisplatin and the cancer is the squamous subtype
of non-small cell lung cancer.
37-53. (canceled)
54. A method of treating cancer in a patient comprising
administering to the patient a compound of Formula I; ##STR00035##
or a pharmaceutically acceptable salt thereof, wherein the
variables are as defined in claim 1; in combination with one or
more of the following additional therapeutic agents: gemcitabine,
cisplatin or carboplatin, ionizing radiation, and etoposide.
55-101. (canceled)
102. The method of any one of claims 1, 8, or 54, wherein the
compound has Formula IA-iii: ##STR00036## wherein Ring A is
##STR00037## J.sup.5o is H, F, Cl, C.sub.1-4aliphatic,
O(C.sub.1-3aliphatic), or OH; J.sup.5p is ##STR00038## J.sup.5p1 is
H, C.sub.1-4aliphatic, oxetanyl, tetrahydrofuranyl,
tetrahydropyranyl; wherein J.sup.5p1 is optionally substituted with
1-2 occurrences of OH or halo; J.sup.5p2 is H, methyl, ethyl,
CH.sub.2F, CF.sub.3, or CH.sub.2OH; J.sup.2o is H, CN, or
SO.sub.2CH.sub.3; J.sup.2m is H, F, Cl, or methyl; J.sup.2p is
--SO.sub.2(C.sub.1-6alkyl), --SO.sub.2(C.sub.3-6cycloalkyl),
--SO.sub.2(4-6 membered heterocyclyl),
--SO.sub.2(C.sub.1-4alkyl)N(C.sub.1-4alkyl).sub.2, or
--SO.sub.2(C.sub.1-4alkyl)-(4-6 membered heterocyclyl), wherein
said heterocyclyl contains 1 heteroatom selected from oxygen,
nitrogen, or sulfur; and wherein said J.sup.2p is optionally
substituted with 1-3 occurrences halo, OH, or
O(C.sub.1-4alkyl).
105. The method of claim 102, wherein the compound is ##STR00039##
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This present invention claims the benefit, under 35 U.S.C.
.sctn.119, of U.S. Provisional Application No. 61/620,717, filed
Apr. 5, 2012, the entire contents of which are incorporated herein
by reference.
BACKGROUND OF THE INVENTION
[0002] ATR ("ATM and Rad3 related") kinase is a protein kinase
involved in cellular responses to DNA damage. ATR kinase acts with
ATM ("ataxia telangiectasia mutated") kinase and many other
proteins to regulate a cell's response to DNA damage, commonly
referred to as the DNA Damage Response ("DDR"). The DDR stimulates
DNA repair, promotes survival and stalls cell cycle progression by
activating cell cycle checkpoints, which provide time for repair.
Without the DDR, cells are much more sensitive to DNA damage and
readily die from DNA lesions induced by endogenous cellular
processes such as DNA replication or exogenous DNA damaging agents
commonly used in cancer therapy.
[0003] Healthy cells can rely on a host of different proteins for
DNA repair including the DDR kinase ATR. In some cases these
proteins can compensate for one another by activating functionally
redundant DNA repair processes. On the contrary, many cancer cells
harbour defects in some of their DNA repair processes, such as ATM
signaling, and therefore display a greater reliance on their
remaining intact DNA repair proteins which include ATR.
[0004] In addition, many cancer cells express activated oncogenes
or lack key tumour suppressors, and this can make these cancer
cells prone to dysregulated phases of DNA replication which in turn
cause DNA damage. ATR has been implicated as a critical component
of the DDR in response to disrupted DNA replication. As a result,
these cancer cells are more dependent on ATR activity for survival
than healthy cells. Accordingly, ATR inhibitors may be useful for
cancer treatment, either used alone or in combination with DNA
damaging agents, because they shut down a DNA repair mechanism that
is more important for cellular survival in many cancer cells than
in healthy normal cells.
[0005] In fact, disruption of ATR function (e.g. by gene deletion)
has been shown to promote cancer cell death both in the absence and
presence of DNA damaging agents. This suggests that ATR inhibitors
may be effective both as single agents and as potent sensitizers to
radiotherapy or genotoxic chemotherapy.
[0006] ATR peptide can be expressed and isolated using a variety of
methods known in the literature (see e.g., Unsal-Kacmaz et al, PNAS
99: 10, pp 6673-6678, May 14, 2002; see also Kumagai et al. Cell
124, pp 943-955, Mar. 10, 2006; Unsal-Kacmaz et al. Molecular and
Cellular Biology, February 2004, p 1292-1300; and Hall-Jackson et
al. Oncogene 1999, 18, 6707-6713).
[0007] For all of these reasons, there is a need for the
development of potent and selective ATR inhibitors for the
treatment of cancer, either as single agents or as part of
combination therapies.
SUMMARY OF THE INVENTION
[0008] The present invention relates to compounds useful as
inhibitors of ATR protein kinase. The invention also relates to
pharmaceutically acceptable compositions comprising the compounds
of this invention; methods of treating of various diseases,
disorders, and conditions using the compounds of this invention;
processes for preparing the compounds of this invention;
intermediates for the preparation of the compounds of this
invention; and methods of using the compounds in in vitro
applications, such as the study of kinases in biological and
pathological phenomena; the study of intracellular signal
transduction pathways mediated by such kinases; and the comparative
evaluation of new kinase inhibitors.
[0009] The compounds of the invention are very potent ATR
inhibitors.
BRIEF DESCRIPTION OF THE FIGURES
[0010] FIG. 1: Clonogenic survival of cancer cells from MDA-MB-231
breast cancer cell line when treated with VE-821, ABT-888, and
ionizing radiation
[0011] FIGS. 2 and 3: Clonogenic survival of cancer cells from RKO
and MDA-MB-231 breast cancer cell line when treated with VE-822,
ABT-888, and ionizing radiation
[0012] FIG. 4: Cancer-selective synergistic effects for the
combination of VE-822 with PARP inhibitor Rucaparib in various
cancer cell lines
[0013] FIG. 5: Cancer-selective synergistic effects for the
combination of VE-822 with PARP inhibitor Rucaparib in a cancer
cell compared to a normal cell
[0014] FIG. 6a: Cancer-selective synergistic effects for the
combination of VE-822, the PARP inhibitor Rucaparib and Ionizing
radiation (IR)
[0015] FIG. 6b: Cancer-selective synergistic effects for the
combination of VE-822, the PARP inhibitor Rucaparib and
cisplatin.
DETAILED DESCRIPTION OF THE INVENTION
[0016] One aspect of the invention provides a compound of Formula
I:
##STR00002##
or a pharmaceutically acceptable salt thereof,
[0017] wherein [0018] R.sup.1 is a 5-6 membered monocyclic aryl or
heteroaryl ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, wherein said monocyclic aryl or
heteroaryl ring is optionally fused to another ring to form an 8-10
membered bicyclic aryl or heteroaryl ring having 0-6 heteroatoms
independently selected from nitrogen, oxygen, or sulfur; each
R.sup.1 is optionally substituted with 1-5 J.sup.1 groups; [0019]
R.sup.2 is a 5-6 membered monocyclic aryl or heteroaryl ring having
0-3 heteroatoms independently selected from nitrogen, oxygen, or
sulfur, wherein said monocyclic aryl or heteroaryl ring is
optionally fused to another ring to form an 8-10 membered bicyclic
aryl or heteroaryl ring having 0-4 heteroatoms independently
selected from nitrogen, oxygen, or sulfur; each R.sup.2 is
optionally substituted with 1-5 J.sup.2 groups; [0020] L is
--C(O)NH-- or --C(O)N(C.sub.1-6alkyl)-; [0021] n is 0 or 1; [0022]
Each J.sup.1 and J.sup.2 is independently halo, --CN, --NO.sub.2,
--V.sup.1--R, or --(V.sup.2).sub.m-Q; [0023] V.sup.1 is a
C.sub.1-10aliphatic chain wherein 0-3 methylene units are
optionally and independently replaced with O, NR'', S, C(O), S(O),
or S(O).sub.2; V.sup.1 is optionally substituted with 1-6
occurrences of J.sup.V1; [0024] V.sup.2 is a C.sub.1-10aliphatic
chain wherein 0-3 methylene units are optionally and independently
replaced with O, NR'', S, C(O), S(O), or S(O).sub.2; V.sup.2 is
optionally substituted with 1-6 occurrences of J.sup.V2; [0025] m
is 0 or 1; [0026] Q is a 3-8 membered saturated or unsaturated
monocyclic ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or a 9-10 membered saturated or
unsaturated bicyclic ring having 0-6 heteroatoms independently
selected from nitrogen, oxygen, or sulfur; each Q is optionally
substituted with 0-5 J.sup.Q; [0027] each J.sup.V1 or J.sup.V2 is
independently halogen, CN, NH.sub.2, NO.sub.2, C.sub.1-4aliphatic,
NH(C.sub.1-4aliphatic), N(C.sub.1-4aliphatic).sub.2, OH,
O(C.sub.1-4aliphatic), CO.sub.2H, CO.sub.2(C.sub.1-4aliphatic),
C(O)NH.sub.2, C(O)NH(C.sub.1-4aliphatic),
C(O)N(C.sub.1-4aliphatic).sub.2, NHCO(C.sub.1-4aliphatic),
N(C.sub.1-4aliphatic)CO(C.sub.1-4aliphatic),
SO.sub.2(C.sub.1-4aliphatic), NHSO.sub.2(C.sub.1-4aliphatic), or
N(C.sub.1-4aliphatic)SO.sub.2(C.sub.1-4aliphatic), wherein said
C.sub.1-4aliphatic is optionally substituted with halo; [0028] R is
H or C.sub.1-6aliphatic wherein said C.sub.1-6aliphatic is
optionally substituted with 1-4 occurrences of NH.sub.2,
NH(C.sub.1-4aliphatic), N(C.sub.1-4aliphatic).sub.2, halogen,
C.sub.1-4aliphatic, OH, O(C.sub.1-4aliphatic), NO.sub.2, CN,
CO.sub.2H, CO.sub.2(C.sub.1-4aliphatic), CO(C.sub.1-4aliphatic),
O(haloC.sub.1-4aliphatic), or haloC.sub.1-4aliphatic; [0029] each
J.sup.Q is independently halo, oxo, CN, NO.sub.2, X--R, or
--(X).sub.p-Q.sup.4; [0030] p is 0 or 1; [0031] X is
C.sub.1-10aliphatic; wherein 1-3 methylene units of said
C.sub.1-6aliphatic are optionally replaced with --NR, --O--, --S--,
C(O), S(O).sub.2, or S(O); wherein X is optionally and
independently substituted with 1-4 occurrences of NH.sub.2,
NH(C.sub.1-4aliphatic), N(C.sub.1-4aliphatic).sub.2, halogen,
C.sub.1-4aliphatic, OH, O(C.sub.1-4aliphatic), NO.sub.2, CN,
CO(C.sub.1-4aliphatic), CO.sub.2H, CO.sub.2(C.sub.1-4aliphatic),
C(O)NH.sub.2, C(O)NH(C.sub.1-4aliphatic),
C(O)N(C.sub.1-4aliphatic).sub.2, SO(C.sub.1-4aliphatic),
SO.sub.2(C.sub.1-4aliphatic), SO.sub.2NH(C.sub.1-4aliphatic),
SO.sub.2N(C.sub.1-4aliphatic).sub.2, NHC(O)(C.sub.1-4aliphatic),
N(C.sub.1-4aliphatic)C(O)(C.sub.1-4aliphatic), wherein said
C.sub.1-4aliphatic is optionally substituted with 1-3 occurrences
of halo; [0032] Q.sup.4 is a 3-8 membered saturated or unsaturated
monocyclic ring having 0-4 heteroatoms independently selected from
nitrogen, oxygen, or sulfur, or a 8-10 membered saturated or
unsaturated bicyclic ring having 0-6 heteroatoms independently
selected from nitrogen, oxygen, or sulfur; each Q.sup.4 is
optionally substituted with 1-5 J.sup.Q4; [0033] J.sup.Q4 is halo,
CN, or C.sub.1-4alkyl wherein up to 2 methylene units are
optionally replaced with O, NR*, S, C(O), S(O), or S(O).sub.2;
[0034] R is H or C.sub.1-4alkyl wherein said C.sub.1-4alkyl is
optionally substituted with 1-4 halo; [0035] R', R'', and R* are
each independently H, C.sub.1-4alkyl, or is absent; wherein said
C.sub.1-4alkyl is optionally substituted with 1-4 halo.
[0036] Another embodiment provides a compound of Formula I for use
in treating cancer with a defect in the ATM signaling cascade or a
base excision repair protein.
[0037] In some embodiments, L is --C(O)NH--; and R.sup.1 and
R.sup.2 are phenyl.
[0038] Another embodiment provides a compound of Formula
IA-iii:
##STR00003##
wherein [0039] Ring A is
[0039] ##STR00004## [0040] J.sup.5o is H, F, Cl,
C.sub.1-4aliphatic, O(C.sub.1-3aliphatic), or OH; [0041] J.sup.5p
is
[0041] ##STR00005## [0042] J.sup.5p1 is H, C.sub.1-4aliphatic,
oxetanyl, tetrahydrofuranyl, tetrahydropyranyl; wherein J.sup.5p1
is optionally substituted with 1-2 occurrences of OH or halo;
[0043] J.sup.5p2 is H, methyl, ethyl, CH.sub.2F, CF.sub.3, or
CH.sub.2OH; [0044] J.sup.2o is H, CN, or SO.sub.2CH.sub.3; [0045]
J.sup.2m is H, F, Cl, or methyl; [0046] J.sup.2p is
--SO.sub.2(C.sub.1-6alkyl), --SO.sub.2(C.sub.3-6cycloalkyl),
--SO.sub.2(4-6 membered heterocyclyl),
--SO.sub.2(C.sub.1-4alkyl)N(C.sub.1-4alkyl).sub.2, or
--SO.sub.2(C.sub.1-4alkyl)-(4-6 membered heterocyclyl), wherein
said heterocyclyl contains 1 heteroatom selected from oxygen,
nitrogen, or sulfur; and wherein said J.sup.2p is optionally
substituted with 1-3 occurrences halo, OH, or
O(C.sub.1-4alkyl).
[0047] In some embodiments, Ring A is
##STR00006##
[0048] In other embodiments, Ring A is
##STR00007##
[0049] Another embodiment provides a compound selected from the
following:
##STR00008##
[0050] In yet another embodiment, the compound is selected from a
compound described in WO 2010/071837.
[0051] In some embodiments, the variables are as depicted in the
compounds of the disclosure including compounds in the tables
herein.
[0052] Compounds of this invention include those described
generally herein, and are further illustrated by the classes,
subclasses, and species disclosed herein. As used herein, the
following definitions shall apply unless otherwise indicated. For
purposes of this invention, the chemical elements are identified in
accordance with the Periodic Table of the Elements, CAS version,
Handbook of Chemistry and Physics, 75.sup.th Ed. Additionally,
general principles of organic chemistry are described in "Organic
Chemistry", Thomas Sorrell, University Science Books, Sausalito:
1999, and "March's Advanced Organic Chemistry", 5.sup.th Ed., Ed.:
Smith, M. B. and March, J., John Wiley & Sons, New York: 2001,
the entire contents of which are hereby incorporated by
reference.
[0053] As described herein, a specified number range of atoms
includes any integer therein. For example, a group having from 1-4
atoms could have 1, 2, 3, or 4 atoms.
[0054] As described herein, compounds of the invention may
optionally be substituted with one or more substituents, such as
are illustrated generally herein, or as exemplified by particular
classes, subclasses, and species of the invention. It will be
appreciated that the phrase "optionally substituted" is used
interchangeably with the phrase "substituted or unsubstituted." In
general, the term "substituted", whether preceded by the term
"optionally" or not, refers to the replacement of hydrogen radicals
in a given structure with the radical of a specified substituent.
Unless otherwise indicated, an optionally substituted group may
have a substituent at each substitutable position of the group, and
when more than one position in any given structure may be
substituted with more than one substituent selected from a
specified group, the substituent may be either the same or
different at every position. Combinations of substituents
envisioned by this invention are preferably those that result in
the formation of stable or chemically feasible compounds.
[0055] Unless otherwise indicated, a substituent connected by a
bond drawn from the center of a ring means that the substituent can
be bonded to any position in the ring. In example i below, for
instance, J.sup.1 can be bonded to any position on the pyridyl
ring. For bicyclic rings, a bond drawn through both rings indicates
that the substituent can be bonded from any position of the
bicyclic ring. In example ii below, for instance, J.sup.1 can be
bonded to the 5-membered ring (on the nitrogen atom, for instance),
and to the 6-membered ring.
##STR00009##
[0056] The term "stable", as used herein, refers to compounds that
are not substantially altered when subjected to conditions to allow
for their production, detection, recovery, purification, and use
for one or more of the purposes disclosed herein. In some
embodiments, a stable compound or chemically feasible compound is
one that is not substantially altered when kept at a temperature of
40.degree. C. or less, in the absence of moisture or other
chemically reactive conditions, for at least a week.
[0057] The term "aliphatic" or "aliphatic group", as used herein,
means a straight-chain (i.e., unbranched), branched, or cyclic,
substituted or unsubstituted hydrocarbon chain that is completely
saturated or that contains one or more units of unsaturation that
has a single point of attachment to the rest of the molecule.
[0058] Unless otherwise specified, aliphatic groups contain 1-20
aliphatic carbon atoms. In some embodiments, aliphatic groups
contain 1-10 aliphatic carbon atoms. In other embodiments,
aliphatic groups contain 1-8 aliphatic carbon atoms. In still other
embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms,
and in yet other embodiments aliphatic groups contain 1-4 aliphatic
carbon atoms. Aliphatic groups may be linear or branched,
substituted or unsubstituted alkyl, alkenyl, or alkynyl groups.
Specific examples include, but are not limited to, methyl, ethyl,
isopropyl, n-propyl, sec-butyl, vinyl, n-butenyl, ethynyl, and
tert-butyl. Aliphatic groups may also be cyclic, or have a
combination of linear or branched and cyclic groups. Examples of
such types of aliphatic groups include, but are not limited to
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl,
--CH.sub.2-cyclopropyl,
CH.sub.2CH.sub.2CH(CH.sub.3)-cyclohexyl.
[0059] The term "cycloaliphatic" (or "carbocycle" or "carbocyclyl")
refers to a monocyclic C.sub.3-C.sub.8 hydrocarbon or bicyclic
C.sub.8-C.sub.12 hydrocarbon that is completely saturated or that
contains one or more units of unsaturation, but which is not
aromatic, that has a single point of attachment to the rest of the
molecule wherein any individual ring in said bicyclic ring system
has 3-7 members. Examples of cycloaliphatic groups include, but are
not limited to, cycloalkyl and cycloalkenyl groups. Specific
examples include, but are not limited to, cyclohexyl,
cyclopropenyl, and cyclobutyl.
[0060] The term "heterocycle", "heterocyclyl", or "heterocyclic" as
used herein means non-aromatic, monocyclic, bicyclic, or tricyclic
ring systems in which one or more ring members are an independently
selected heteroatom. In some embodiments, the "heterocycle",
"heterocyclyl", or "heterocyclic" group has three to fourteen ring
members in which one or more ring members is a heteroatom
independently selected from oxygen, sulfur, nitrogen, or
phosphorus, and each ring in the system contains 3 to 7 ring
members.
[0061] Examples of heterocycles include, but are not limited to,
3-1H-benzimidazol-2-one, 3-(1-alkyl)-benzimidazol-2-one,
2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl,
3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino,
2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino,
1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl,
1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl,
3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl,
3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl,
5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl,
4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl,
1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl,
5-imidazolidinyl, indolinyl, tetrahydroquinolinyl,
tetrahydroisoquinolinyl, benzothiolane, benzodithiane, and
1,3-dihydro-imidazol-2-one.
[0062] Cyclic groups, (e.g. cycloaliphatic and heterocycles), can
be linearly fused, bridged, or spirocyclic.
[0063] The term "heteroatom" means one or more of oxygen, sulfur,
nitrogen, phosphorus, or silicon (including, any oxidized form of
nitrogen, sulfur, phosphorus, or silicon; the quaternized form of
any basic nitrogen or; a substitutable nitrogen of a heterocyclic
ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in
pyrrolidinyl) or NR.sup.+ (as in N-substituted pyrrolidinyl)).
[0064] The term "unsaturated", as used herein, means that a moiety
has one or more units of unsaturation. As would be known by one of
skill in the art, unsaturated groups can be partially unsaturated
or fully unsaturated. Examples of partially unsaturated groups
include, but are not limited to, butene, cyclohexene, and
tetrahydropyridine. Fully unsaturated groups can be aromatic,
anti-aromatic, or non-aromatic. Examples of fully unsaturated
groups include, but are not limited to, phenyl, cyclooctatetraene,
pyridyl, thienyl, and 1-methylpyridin-2(1H)-one.
[0065] The term "alkoxy", or "thioalkyl", as used herein, refers to
an alkyl group, as previously defined, attached through an oxygen
("alkoxy") or sulfur ("thioalkyl") atom.
[0066] The terms "haloalkyl", "haloalkenyl", "haloaliphatic", and
"haloalkoxy" mean alkyl, alkenyl or alkoxy, as the case may be,
substituted with one or more halogen atoms. This term includes
perfluorinated alkyl groups, such as --CF.sub.3 and
--CF.sub.2CF.sub.3.
[0067] The terms "halogen", "halo", and "hal" mean F, Cl, Br, or
I.
[0068] The term "aryl" used alone or as part of a larger moiety as
in "aralkyl", "aralkoxy", or "aryloxyalkyl", refers to monocyclic,
bicyclic, and tricyclic ring systems having a total of five to
fourteen ring members, wherein at least one ring in the system is
aromatic and wherein each ring in the system contains 3 to 7 ring
members. The term "aryl" may be used interchangeably with the term
"aryl ring".
[0069] The term "heteroaryl", used alone or as part of a larger
moiety as in "heteroaralkyl" or "heteroarylalkoxy", refers to
monocyclic, bicyclic, and tricyclic ring systems having a total of
five to fourteen ring members, wherein at least one ring in the
system is aromatic, at least one ring in the system contains one or
more heteroatoms, and wherein each ring in the system contains 3 to
7 ring members. The term "heteroaryl" may be used interchangeably
with the term "heteroaryl ring" or the term "heteroaromatic".
Examples of heteroaryl rings include, but are not limited to,
2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl,
5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl,
5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl,
2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl,
2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g.,
3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl
(e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and
5-triazolyl), 2-thienyl, 3-thienyl, benzofuryl, benzothiophenyl,
indolyl (e.g., 2-indolyl), pyrazolyl (e.g., 2-pyrazolyl),
isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl,
1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl,
1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, purinyl, pyrazinyl,
1,3,5-triazinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl,
4-quinolinyl), and isoquinolinyl (e.g., 1-isoquinolinyl,
3-isoquinolinyl, or 4-isoquinolinyl).
[0070] It shall be understood that the term "heteroaryl" includes
certain types of heteroaryl rings that exist in equilibrium between
two different forms. More specifically, for example, species such
hydropyridine and pyridinone (and likewise hydroxypyrimidine and
pyrimidinone) are meant to be encompassed within the definition of
"heteroaryl."
##STR00010##
[0071] The term "protecting group" and "protective group" as used
herein, are interchangeable and refer to an agent used to
temporarily block one or more desired functional groups in a
compound with multiple reactive sites. In certain embodiments, a
protecting group has one or more, or preferably all, of the
following characteristics: a) is added selectively to a functional
group in good yield to give a protected substrate that is b) stable
to reactions occurring at one or more of the other reactive sites;
and c) is selectively removable in good yield by reagents that do
not attack the regenerated, deprotected functional group. As would
be understood by one skilled in the art, in some cases, the
reagents do not attack other reactive groups in the compound. In
other cases, the reagents may also react with other reactive groups
in the compound. Examples of protecting groups are detailed in
Greene, T. W., Wuts, P. G in "Protective Groups in Organic
Synthesis", Third Edition, John Wiley & Sons, New York: 1999
(and other editions of the book), the entire contents of which are
hereby incorporated by reference. The term "nitrogen protecting
group", as used herein, refers to an agent used to temporarily
block one or more desired nitrogen reactive sites in a
multifunctional compound. Preferred nitrogen protecting groups also
possess the characteristics exemplified for a protecting group
above, and certain exemplary nitrogen protecting groups are also
detailed in Chapter 7 in Greene, T. W., Wuts, P. G in "Protective
Groups in Organic Synthesis", Third Edition, John Wiley & Sons,
New York: 1999, the entire contents of which are hereby
incorporated by reference.
[0072] In some embodiments, a methylene unit of an alkyl or
aliphatic chain is optionally replaced with another atom or group.
Examples of such atoms or groups include, but are not limited to,
nitrogen, oxygen, sulfur, --C(O)--, --C(.dbd.N--CN)--,
--C(.dbd.NR)--, --C(.dbd.NOR)--, --SO--, and --SO.sub.2--. These
atoms or groups can be combined to form larger groups. Examples of
such larger groups include, but are not limited to, --OC(O)--,
--C(O)CO--, --CO.sub.2--, --C(O)NR--, --C(.dbd.N--CN), --NRCO--,
--NRC(O)O--, --SO.sub.2NR--, --NRSO.sub.2--, --NRC(O)NR--,
--OC(O)NR--, and --NRSO.sub.2NR--, wherein R is, for example, H or
C.sub.1-6aliphatic. It should be understood that these groups can
be bonded to the methylene units of the aliphatic chain via single,
double, or triple bonds. An example of an optional replacement
(nitrogen atom in this case) that is bonded to the aliphatic chain
via a double bond would be --CH.sub.2CH.dbd.N--CH.sub.3. In some
cases, especially on the terminal end, an optional replacement can
be bonded to the aliphatic group via a triple bond. One example of
this would be CH.sub.2CH.sub.2CH.sub.2C.ident.N. It should be
understood that in this situation, the terminal nitrogen is not
bonded to another atom.
[0073] It should also be understood that, the term "methylene unit"
can also refer to branched or substituted methylene units. For
example, in an isopropyl moiety [--CH(CH.sub.3).sub.2], a nitrogen
atom (e.g. NR) replacing the first recited "methylene unit" would
result in dimethylamine [--N(CH.sub.3).sub.2]. In instances such as
these, one of skill in the art would understand that the nitrogen
atom will not have any additional atoms bonded to it, and the "R"
from "NR" would be absent in this case.
[0074] Unless otherwise indicated, the optional replacements form a
chemically stable compound. Optional replacements can occur both
within the chain and/or at either end of the chain; i.e. both at
the point of attachment and/or also at the terminal end. Two
optional replacements can also be adjacent to each other within a
chain so long as it results in a chemically stable compound. For
example, a C.sub.3 aliphatic can be optionally replaced by 2
nitrogen atoms to form --C--N.ident.N. The optional replacements
can also completely replace all of the carbon atoms in a chain. For
example, a C.sub.3 aliphatic can be optionally replaced by --NR--,
--C(O)--, and --NR-- to form --NRC(O)NR-- (a urea).
[0075] Unless otherwise indicated, if the replacement occurs at the
terminal end, the replacement atom is bound to a hydrogen atom on
the terminal end. For example, if a methylene unit of
--CH.sub.2CH.sub.2CH.sub.3 were optionally replaced with --O--, the
resulting compound could be --OCH.sub.2CH.sub.3,
--CH.sub.2OCH.sub.3, or --CH.sub.2CH.sub.2OH. It should be
understood that if the terminal atom does not contain any free
valence electrons, then a hydrogen atom is not required at the
terminal end (e.g., --CH.sub.2CH.sub.2CH.dbd.O or
--CH.sub.2CH.sub.2C.ident.N).
[0076] Unless otherwise indicated, structures depicted herein are
also meant to include all isomeric (e.g., enantiomeric,
diastereomeric, geometric, conformational, and rotational) forms of
the structure. For example, the R and S configurations for each
asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E)
conformational isomers are included in this invention. As would be
understood to one skilled in the art, a substituent can freely
rotate around any rotatable bonds. For example, a substituent drawn
as
##STR00011##
also represents
##STR00012##
[0077] Therefore, single stereochemical isomers as well as
enantiomeric, diastereomeric, geometric, conformational, and
rotational mixtures of the present compounds are within the scope
of the invention.
[0078] Unless otherwise indicated, all tautomeric forms of the
compounds of the invention are within the scope of the
invention.
[0079] Additionally, unless otherwise indicated, structures
depicted herein are also meant to include compounds that differ
only in the presence of one or more isotopically enriched atoms.
For example, compounds having the present structures except for the
replacement of hydrogen by deuterium or tritium, or the replacement
of a carbon by a .sup.13C- or .sup.14C-enriched carbon are within
the scope of this invention. Such compounds are useful, for
example, as analytical tools or probes in biological assays.
Pharmaceutically Acceptable Salts
[0080] The compounds of this invention can exist in free form for
treatment, or where appropriate, as a pharmaceutically acceptable
salt.
[0081] A "pharmaceutically acceptable salt" means any non-toxic
salt of a compound of this invention that, upon administration to a
recipient, is capable of providing, either directly or indirectly,
a compound of this invention or an inhibitorily active metabolite
or residue thereof. As used herein, the term "inhibitorily active
metabolite or residue thereof" means that a metabolite or residue
thereof is also an inhibitor of the ATR protein kinase.
[0082] Pharmaceutically acceptable salts are well known in the art.
For example, S. M. Berge et al., describe pharmaceutically
acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66,
1-19, incorporated herein by reference. Pharmaceutically acceptable
salts of the compounds of this invention include those derived from
suitable inorganic and organic acids and bases. These salts can be
prepared in situ during the final isolation and purification of the
compounds. Acid addition salts can be prepared by 1) reacting the
purified compound in its free-based form with a suitable organic or
inorganic acid and 2) isolating the salt thus formed.
[0083] Examples of pharmaceutically acceptable, nontoxic acid
addition salts are salts of an amino group formed with inorganic
acids such as hydrochloric acid, hydrobromic acid, phosphoric acid,
sulfuric acid and perchloric acid or with organic acids such as
acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid,
succinic acid or malonic acid or by using other methods used in the
art such as ion exchange. Other pharmaceutically acceptable salts
include adipate, alginate, ascorbate, aspartate, benzenesulfonate,
benzoate, bisulfate, borate, butyrate, camphorate,
camphorsulfonate, citrate, cyclopentanepropionate, digluconate,
dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate,
glycerophosphate, glycolate, gluconate, glycolate, hemisulfate,
heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide,
2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl
sulfate, malate, maleate, malonate, methanesulfonate,
2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate,
palmitate, palmoate, pectinate, persulfate, 3-phenylpropionate,
phosphate, picrate, pivalate, propionate, salicylate, stearate,
succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate,
undecanoate, valerate salts, and the like.
[0084] Base addition salts can be prepared by 1) reacting the
purified compound in its acid form with a suitable organic or
inorganic base and 2) isolating the salt thus formed. Salts derived
from appropriate bases include alkali metal (e.g., sodium, lithium,
and potassium), alkaline earth metal (e.g., magnesium and calcium),
ammonium and N.sup.+(C.sub.1-4alkyl).sub.4 salts. This invention
also envisions the quaternization of any basic nitrogen-containing
groups of the compounds disclosed herein. Water or oil-soluble or
dispersible products may be obtained by such quaternization.
[0085] Further pharmaceutically acceptable salts include, when
appropriate, nontoxic ammonium, quaternary ammonium, and amine
cations formed using counterions such as halide, hydroxide,
carboxylate, sulfate, phosphate, nitrate, lower alkyl sulfonate and
aryl sulfonate. Other acids and bases, while not in themselves
pharmaceutically acceptable, may be employed in the preparation of
salts useful as intermediates in obtaining the compounds of the
invention and their pharmaceutically acceptable acid or base
addition salts.
Abbreviations
[0086] The following abbreviations are used:
DMSO dimethyl sulfoxide ATP adenosine triphosphate .sup.1HNMR
proton nuclear magnetic resonance HPLC high performance liquid
chromatography LCMS liquid chromatography-mass spectrometry TLC
thin layer chromatography Rt retention time
Compound Uses
[0087] One aspect of this invention provides compounds that are
inhibitors of ATR kinase, and thus are useful for treating or
lessening the severity of a disease, condition, or disorder where
ATR is implicated in the disease, condition, or disorder.
[0088] Another aspect of this invention provides compounds that are
useful for the treatment of diseases, disorders, and conditions
characterized by excessive or abnormal cell proliferation. Such
diseases include, a proliferative or hyperproliferative disease.
Examples of proliferative and hyperproliferative diseases include,
without limitation, cancer and myeloproliferative disorders.
[0089] In some embodiments, said compounds are selected from the
group consisting of a compound of formula I. The term "cancer"
includes, but is not limited to the following types of cancers:
oral, lung, gastrointestinal, genitourinary tract, liver, bone,
nervous system, gynecological, skin, thyroid gland, or adrenal
gland. More specifically, "cancer" includes, but is not limited to
the following cancers: Oral: buccal cavity, lip, tongue, mouth,
pharynx; Cardiac: sarcoma (angiosarcoma, fibrosarcoma,
rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma, fibroma,
lipoma and teratoma; Lung: bronchogenic carcinoma (squamous cell or
epidermoid, undifferentiated small cell, undifferentiated large
cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial
adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma;
Gastrointestinal: esophagus (squamous cell carcinoma, larynx,
adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma,
lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma,
insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma),
small bowel or small intestines (adenocarcinoma, lymphoma,
carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma,
neurofibroma, fibroma), large bowel or large intestines
(adenocarcinoma, tubular adenoma, villous adenoma, hamartoma,
leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinary
tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma],
lymphoma, leukemia), bladder and urethra (squamous cell carcinoma,
transitional cell carcinoma, adenocarcinoma), prostate
(adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal
carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial
cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma);
Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma,
hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma,
biliary passages; Bone: osteogenic sarcoma (osteosarcoma),
fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma,
Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma),
multiple myeloma, malignant giant cell tumor chordoma,
osteochronfroma (osteocartilaginous exostoses), benign chondroma,
chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell
tumors; Nervous system: skull (osteoma, hemangioma, granuloma,
xanthoma, osteitis deformans), meninges (meningioma,
meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma,
glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform,
oligodendroglioma, schwannoma, retinoblastoma, congenital tumors),
spinal cord neurofibroma, meningioma, glioma, sarcoma);
Gynecological: uterus (endometrial carcinoma), cervix (cervical
carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian
carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma,
unclassified carcinoma], granulosa-thecal cell tumors,
Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma),
vulva (squamous cell carcinoma, intraepithelial carcinoma,
adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell
carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal
rhabdomyosarcoma), fallopian tubes (carcinoma), breast;
Hematologic: blood (myeloid leukemia [acute and chronic], acute
lymphoblastic leukemia, chronic lymphocytic leukemia,
myeloproliferative diseases, multiple myeloma, myelodysplastic
syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant
lymphoma] hairy cell; lymphoid disorders; Skin: malignant melanoma,
basal cell carcinoma, squamous cell carcinoma, Karposi's sarcoma,
keratoacanthoma, moles dysplastic nevi, lipoma, angioma,
dermatofibroma, keloids, psoriasis, Thyroid gland: papillary
thyroid carcinoma, follicular thyroid carcinoma, undifferentiated
thyroid cancer, medullary thyroid carcinoma, multiple endocrine
neoplasia type 2A, multiple endocrine neoplasia type 2B, familial
medullary thyroid cancer, pheochromocytoma, paraganglioma; and
Adrenal glands: neuroblastoma.
[0090] In some embodiments, the cancer is selected from a cancer of
the lung or the pancreas. In other embodiments, the cancer is
selected from lung cancer, head and neck cancer, pancreatic cancer,
gastric cancer, or brain cancer. In yet other embodiments, the
cancer is selected from non-small cell lung cancer, small cell lung
cancer, pancreatic cancer, biliary tract cancer, head and neck
cancer, bladder cancer, colorectal cancer, glioblastoma, esophageal
cancer, breast cancer, hepatocellular carcinoma, or ovarian
cancer.
[0091] Thus, the term "cancerous cell" as provided herein, includes
a cell afflicted by any one of the above-identified conditions. In
some embodiments, the cancer is selected from colorectal, thyroid,
or breast cancer.
[0092] The term "myeloproliferative disorders", includes disorders
such as polycythemia vera, thrombocythemia, myeloid metaplasia with
myelofibrosis, hypereosinophilic syndrome, juvenile myelomonocytic
leukemia, systemic mast cell disease, and hematopoietic disorders,
in particular, acute-myelogenous leukemia (AML),
chronic-myelogenous leukemia (CML), acute-promyelocytic leukemia
(APL), and acute lymphocytic leukemia (ALL).
Pharmaceutically Acceptable Derivatives or Prodrugs
[0093] In addition to the compounds of this invention,
pharmaceutically acceptable derivatives or prodrugs of the
compounds of this invention may also be employed in compositions to
treat or prevent the herein identified disorders.
[0094] The compounds of this invention can also exist as
pharmaceutically acceptable derivatives.
[0095] A "pharmaceutically acceptable derivative" is an adduct or
derivative which, upon administration to a patient in need, is
capable of providing, directly or indirectly, a compound as
otherwise described herein, or a metabolite or residue thereof.
Examples of pharmaceutically acceptable derivatives include, but
are not limited to, esters and salts of such esters.
[0096] A "pharmaceutically acceptable derivative or prodrug" means
any pharmaceutically acceptable ester, salt of an ester or other
derivative or salt thereof of a compound, of this invention which,
upon administration to a recipient, is capable of providing, either
directly or indirectly, a compound of this invention or an
inhibitorily active metabolite or residue thereof. Particularly
favoured derivatives or prodrugs are those that increase the
bioavailability of the compounds of this invention when such
compounds are administered to a patient (e.g., by allowing an
orally administered compound to be more readily absorbed into the
blood) or which enhance delivery of the parent compound to a
biological compartment (e.g., the brain or lymphatic system)
relative to the parent species.
[0097] Pharmaceutically acceptable prodrugs of the compounds of
this invention include, without limitation, esters, amino acid
esters, phosphate esters, metal salts and sulfonate esters.
Pharmaceutical Compositions
[0098] The present invention also provides compounds and
compositions that are useful as inhibitors of ATR kinase.
[0099] One aspect of this invention provides pharmaceutically
acceptable compositions that comprise any of the compounds as
described herein, and optionally comprise a pharmaceutically
acceptable carrier, adjuvant or vehicle.
[0100] The pharmaceutically acceptable carrier, adjuvant, or
vehicle, as used herein, includes any and all solvents, diluents,
or other liquid vehicle, dispersion or suspension aids, surface
active agents, isotonic agents, thickening or emulsifying agents,
preservatives, solid binders, lubricants and the like, as suited to
the particular dosage form desired. Remington's Pharmaceutical
Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co.,
Easton, Pa., 1980) discloses various carriers used in formulating
pharmaceutically acceptable compositions and known techniques for
the preparation thereof. Except insofar as any conventional carrier
medium is incompatible with the compounds of the invention, such as
by producing any undesirable biological effect or otherwise
interacting in a deleterious manner with any other component(s) of
the pharmaceutically acceptable composition, its use is
contemplated to be within the scope of this invention.
[0101] Some examples of materials which can serve as
pharmaceutically acceptable carriers include, but are not limited
to, ion exchangers, alumina, aluminum stearate, lecithin, serum
proteins, such as human serum albumin, buffer substances such as
phosphates, glycine, sorbic acid, or potassium sorbate, partial
glyceride mixtures of saturated vegetable fatty acids, water, salts
or electrolytes, such as protamine sulfate, disodium hydrogen
phosphate, potassium hydrogen phosphate, sodium chloride, zinc
salts, colloidal silica, magnesium trisilicate, polyvinyl
pyrrolidone, polyacrylates, waxes,
polyethylene-polyoxypropylene-block polymers, wool fat, sugars such
as lactose, glucose and sucrose; starches such as corn starch and
potato starch; cellulose and its derivatives such as sodium
carboxymethyl cellulose, ethyl cellulose and cellulose acetate;
powdered tragacanth; malt; gelatin; talc; excipients such as cocoa
butter and suppository waxes; oils such as peanut oil, cottonseed
oil; safflower oil; sesame oil; olive oil; corn oil and soybean
oil; glycols; such a propylene glycol or polyethylene glycol;
esters such as ethyl oleate and ethyl laurate; agar; buffering
agents such as magnesium hydroxide and aluminum hydroxide; alginic
acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl
alcohol, and phosphate buffer solutions, as well as other non-toxic
compatible lubricants such as sodium lauryl sulfate and magnesium
stearate, as well as coloring agents, releasing agents, coating
agents, sweetening, flavoring and perfuming agents, preservatives
and antioxidants can also be present in the composition, according
to the judgment of the formulator.
Combination Therapies
[0102] Another aspect of this invention is directed towards a
method of treating cancer in a subject in need thereof, comprising
administration of a compound of this invention or a
pharmaceutically acceptable salt thereof, and an additional
therapeutic agent. In some embodiments, said method comprises the
sequential or co-administration of the compound or a
pharmaceutically acceptable salt thereof, and the additional
therapeutic agent.
[0103] In some embodiments, said additional therapeutic agent is an
anti-cancer agent. In other embodiments, said additional
therapeutic agent is a DNA-damaging agent. It shall be understood
that the additional therapeutic agent may comprise one or more
therapies. In yet other embodiments, said additional therapeutic
agent is selected from radiation therapy, chemotherapy, or other
agents typically used in combination with radiation therapy or
chemotherapy, such as radiosensitizers and chemosensitizers. In yet
other embodiments, said additional therapeutic agent is ionizing
radiation. In some embodiments, said additional therapeutic agent
comprises ionizing radiation and a DNA-damaging agent.
[0104] As would be known by one of skill in the art,
radiosensitizers are agents that can be used in combination with
radiation therapy. Radiosensitizers work in various different ways,
including, but not limited to, making cancer cells more sensitive
to radiation therapy, working in synergy with radiation therapy to
provide an improved synergistic effect, acting additively with
radiation therapy, or protecting surrounding healthy cells from
damage caused by radiation therapy. Likewise chemosensitizers are
agents that can be used in combination with chemotherapy.
Similarly, chemosensitizers work in various different ways,
including, but not limited to, making cancer cells more sensitive
to chemotherapy, working in synergy with chemotherapy to provide an
improved synergistic effect, acting additively to chemotherapy, or
protecting surrounding healthy cells from damage caused by
chemotherapy.
[0105] Examples of DNA-damaging agents that may be used in
combination with compounds of this invention include, but are not
limited to Platinating agents, such as Carboplatin, Nedaplatin,
Satraplatin and other derivatives; Topo I inhibitors, such as
Topotecan, irinotecan/SN38, rubitecan and other derivatives; Topo
II inhibitors, such as Etoposide (VP-16), Daunorubicin,
Doxorubicin, Mitoxantrone, Aclarubicin, Epirubicin, Idarubicin,
Amrubicin, Amsacrine, Pirarubicin, Valrubicin, Zorubicin,
Teniposide and other derivatives; Antimetabolites, such as Folic
family (Methotrexate, Pemetrexed and relatives); Purine antagonists
and Pyrimidine antagonists (Thioguanine, Fludarabine, Cladribine,
Cytarabine, Gemcitabine, 6-Mercaptopurine, 5-Fluorouracil (5FU) and
relatives); Alkylating agents, such as Nitrogen mustards
(Cyclophosphamide, Melphalan, Chlorambucil, mechlorethamine,
Ifosfamide and relatives); nitrosoureas (eg Carmustine); Triazenes
(Dacarbazine, temozolomide); Alkyl sulphonates (eg Busulfan);
Procarbazine and Aziridines; Antibiotics, such as Hydroxyurea,
Anthracyclines (doxorubicin, daunorubicin, epirubicin and other
derivatives); Anthracenediones (Mitoxantrone and relatives);
Streptomyces family (Bleomycin, Mitomycin C, actinomycin); and
Ultraviolet light.
[0106] Other therapies or anticancer agents that may be used in
combination with the inventive agents of the present invention
include surgery, radiotherapy (in but a few examples,
gamma-radiation, neutron beam radiotherapy, electron beam
radiotherapy, proton therapy, brachytherapy, and systemic
radioactive isotopes, to name a few), endocrine therapy, biologic
response modifiers (interferons, interleukins, and tumor necrosis
factor (TNF) to name a few), hyperthermia and cryotherapy, agents
to attenuate any adverse effects (e.g., antiemetics), and other
approved chemotherapeutic drugs, including, but not limited to, the
DNA damaging agents listed herein, spindle poisons (Vinblastine,
Vincristine, Vinorelbine, Paclitaxel), podophyllotoxins (Etoposide,
Irinotecan, Topotecan), nitrosoureas (Carmustine, Lomustine),
inorganic ions (Cisplatin, Carboplatin), enzymes (Asparaginase),
and hormones (Tamoxifen, Leuprolide, Flutamide, and Megestrol),
Gleevec.TM., adriamycin, dexamethasone, and cyclophosphamide.
[0107] A compound of the instant invention may also be useful for
treating cancer in combination with any of the following
therapeutic agents: abarelix (Plenaxis Depot.RTM.); aldesleukin
(Prokine.RTM.); Aldesleukin (Proleukin.RTM.); Alemtuzumabb
(Campath.RTM.); alitretinoin (Panretin.RTM.); allopurinol
(Zyloprim.RTM.); altretamine (Hexylen.RTM.); amifostine
(Ethyol.RTM.); anastrozole (Arimidex.RTM.); arsenic trioxide
(Trisenox.RTM.); asparaginase (Elspar.RTM.); azacitidine
(Vidaza.RTM.); bevacuzimab (Avastin.RTM.); bexarotene capsules
(Targretin.RTM.); bexarotene gel (Targretin.RTM.); bleomycin
(Blenoxane.RTM.); bortezomib (Velcade.RTM.); busulfan intravenous
(Busulfex.RTM.); busulfan oral (Myleran.RTM.); calusterone
(Methosarb.RTM.); capecitabine (Xeloda.RTM.); carboplatin
(Paraplatin.RTM.); carmustine (BCNU.RTM., BiCNU.RTM.); carmustine
(Gliadel.RTM.); carmustine with Polifeprosan 20 Implant (Gliadel
Wafer.RTM.); celecoxib (Celebrex.RTM.); cetuximab (Erbitux.RTM.);
chlorambucil (Leukeran.RTM.); cisplatin (Platinol.RTM.); cladribine
(Leustatin.RTM., 2-CdA.RTM.); clofarabine (Clolar.RTM.);
cyclophosphamide (Cytoxan.RTM., Neosar.RTM.); cyclophosphamide
(Cytoxan Injection.RTM.); cyclophosphamide (Cytoxan Tablet.RTM.);
cytarabine (Cytosar-U.RTM.); cytarabine liposomal (DepoCyt.RTM.);
dacarbazine (DTIC-Dome.RTM.); dactinomycin, actinomycin D
(Cosmegen.RTM.); Darbepoetin alfa (Aranesp.RTM.); daunorubicin
liposomal (DanuoXome.RTM.); daunorubicin, daunomycin
(Daunorubicin.RTM.); daunorubicin, daunomycin (Cerubidine.RTM.);
Denileukin diftitox (Ontak.RTM.); dexrazoxane (Zinecard.RTM.);
docetaxel (Taxotere.RTM.); doxorubicin (Adriamycin PFS.RTM.);
doxorubicin (Adriamycin.RTM., Rubex.RTM.); doxorubicin (Adriamycin
PFS Injection.RTM.); doxorubicin liposomal (Doxil.RTM.);
dromostanolone propionate (Dromostanolone.RTM.); dromostanolone
propionate (masterone Injection.RTM.); Elliott's B Solution
(Elliott's B Solution.RTM.); epirubicin (Ellence.RTM.); Epoetin
alfa (Epogen.RTM.); erlotinib (Tarceva.RTM.); estramustine
(Emcyt.RTM.); etoposide phosphate (Etopophos.RTM.); etoposide,
VP-16 (Vepesid.RTM.); exemestane (Aromasin.RTM.); Filgrastim
(Neupogen.RTM.); floxuridine (intraarterial) (FUDR.RTM.);
fludarabine (Fludara.RTM.); fluorouracil, 5-FU (Adrucil.RTM.);
fulvestrant (Faslodex.RTM.); gefitinib (Iressa.RTM.); gemcitabine
(Gemzar.RTM.); gemtuzumab ozogamicin (Mylotarg.RTM.); goserelin
acetate (Zoladex Implant.RTM.); goserelin acetate (Zoladex.RTM.);
histrelin acetate (Histrelin Implant.RTM.); hydroxyurea
(Hydrea.RTM.); Ibritumomab Tiuxetan (Zevalin.RTM.); idarubicin
(Idamycin.RTM.); ifosfamide (IFEX.RTM.); imatinib mesylate
(Gleevec.RTM.); interferon alfa 2a (Roferon A.RTM.); Interferon
alfa-2b (Intron A.RTM.); irinotecan (Camptosar.RTM.); lenalidomide
(Revlimid.RTM.); letrozole (Ferrara.RTM.); leucovorin
(Wellcovorin.RTM., Leucovorin.RTM.); Leuprolide Acetate
(Eligard.RTM.); levamisole (Ergamisol.RTM.); lomustine, CCNU
(CeeBU.RTM.); meclorethamine, nitrogen mustard (Mustargen.RTM.);
megestrol acetate (Megace.RTM.); melphalan, L-PAM (Alkeran.RTM.);
mercaptopurine, 6-MP (Purinethol.RTM.); mesna (Mesnex.RTM.); mesna
(Mesnex Tabs.RTM.); methotrexate (Methotrexate.RTM.); methoxsalen
(Uvadex.RTM.); mitomycin C (Mutamycin.RTM.); mitotane
(Lysodren.RTM.); mitoxantrone (Novantrone.RTM.); nandrolone
phenpropionate (Durabolin-50.RTM.); nelarabine (Arranon.RTM.);
Nofetumomab (Verluma.RTM.); Oprelvekin (Neumega.RTM.); oxaliplatin
(Eloxatin.RTM.); paclitaxel (Paxene.RTM.); paclitaxel (Taxol.RTM.);
paclitaxel protein-bound particles (Abraxane.RTM.); palifermin
(Kepivance.RTM.); pamidronate (Aredia.RTM.); pegademase (Adagen
(Pegademase Bovine).RTM.); pegaspargase (Oncaspar.RTM.);
Pegfilgrastim (Neulasta.RTM.); pemetrexed disodium (Alimta.RTM.);
pentostatin (Nipent.RTM.); pipobroman (Vercyte.RTM.); plicamycin,
mithramycin (Mithracin.RTM.); porfimer sodium (Photofrin.RTM.);
procarbazine (Matulane.RTM.); quinacrine (Atabrine.RTM.);
Rasburicase (Elitek.RTM.); Rituximab (Rituxan.RTM.); sargramostim
(Leukine.RTM.); Sargramostim (Prokine.RTM.); sorafenib
(Nexavar.RTM.); streptozocin (Zanosar.RTM.); sunitinib maleate
(Sutent.RTM.); talc (Sclerosol.RTM.); tamoxifen (Nolvadex.RTM.);
temozolomide (Temodar.RTM.); teniposide, VM-26 (Vumon.RTM.);
testolactone (Teslac.RTM.); thioguanine, 6-TG (Thioguanine.RTM.);
thiotepa (Thioplex.RTM.); topotecan (Hycamtin.RTM.); toremifene
(Fareston.RTM.); Tositumomab (Bexxar.RTM.); Tositumomab/I-131
tositumomab (Bexxar.RTM.); Trastuzumab (Herceptin.RTM.); tretinoin,
ATRA (Vesanoid.RTM.); Uracil Mustard (Uracil Mustard
Capsules.RTM.); valrubicin (Valstar.RTM.); vinblastine
(Velban.RTM.); vincristine (Oncovin.RTM.); vinorelbine
(Navelbine.RTM.); zoledronate (Zometa.RTM.) and vorinostat
(Zolinza.RTM.).
[0108] For a comprehensive discussion of updated cancer therapies
see, http://www.nci.nih.gov/, a list of the FDA approved oncology
drugs at http://www.fda.gov/cder/cancer/druglistframe.htm, and The
Merck Manual, Seventeenth Ed. 1999, the entire contents of which
are hereby incorporated by reference.
Compositions for Administration into a Subject
[0109] The ATR kinase inhibitors or pharmaceutical salts thereof
may be formulated into pharmaceutical compositions for
administration to animals or humans. These pharmaceutical
compositions, which comprise an amount of the ATR inhibitor
effective to treat or prevent the diseases or conditions described
herein and a pharmaceutically acceptable carrier, are another
embodiment of the present invention.
[0110] The exact amount of compound required for treatment will
vary from subject to subject, depending on the species, age, and
general condition of the subject, the severity of the infection,
the particular agent, its mode of administration, and the like. The
compounds of the invention are preferably formulated in dosage unit
form for ease of administration and uniformity of dosage. The
expression "dosage unit form" as used herein refers to a physically
discrete unit of agent appropriate for the patient to be treated.
It will be understood, however, that the total daily usage of the
compounds and compositions of the present invention will be decided
by the attending physician within the scope of sound medical
judgment. The specific effective dose level for any particular
patient or organism will depend upon a variety of factors including
the disorder being treated and the severity of the disorder; the
activity of the specific compound employed; the specific
composition employed; the age, body weight, general health, sex and
diet of the patient; the time of administration, route of
administration, and rate of excretion of the specific compound
employed; the duration of the treatment; drugs used in combination
or coincidental with the specific compound employed, and like
factors well known in the medical arts. The term "patient", as used
herein, means an animal, preferably a mammal, and most preferably a
human.
[0111] In some embodiments, these compositions optionally further
comprise one or more additional therapeutic agents. For example,
chemotherapeutic agents or other anti-proliferative agents may be
combined with the compounds of this invention to treat
proliferative diseases and cancer. Examples of known agents with
which these compositions can be combined are listed above under the
"Combination Therapies" section and also throughout the
specification. Some embodiments provide a simultaneous, separate or
sequential use of a combined preparation.
Modes of Administration and Dosage Forms
[0112] The pharmaceutically acceptable compositions of this
invention can be administered to humans and other animals orally,
rectally, parenterally, intracisternally, intravaginally,
intraperitoneally, topically (as by powders, ointments, or drops),
bucally, as an oral or nasal spray, or the like, depending on the
severity of the infection being treated. In certain embodiments,
the compounds of the invention may be administered orally or
parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg
and preferably from about 1 mg/kg to about 25 mg/kg, of subject
body weight per day, one or more times a day, to obtain the desired
therapeutic effect.
[0113] Liquid dosage forms for oral administration include, but are
not limited to, pharmaceutically acceptable emulsions,
microemulsions, solutions, suspensions, syrups and elixirs. In
addition to the active compounds, the liquid dosage forms may
contain inert diluents commonly used in the art such as, for
example, water or other solvents, solubilizing agents and
emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl
carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate,
propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in
particular, cottonseed, groundnut, corn, germ, olive, castor, and
sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene
glycols and fatty acid esters of sorbitan, and mixtures thereof.
Besides inert diluents, the oral compositions can also include
adjuvants such as wetting agents, emulsifying and suspending
agents, sweetening, flavoring, and perfuming agents.
[0114] Injectable preparations, for example, sterile injectable
aqueous or oleaginous suspensions may be formulated according to
the known art using suitable dispersing or wetting agents and
suspending agents. The sterile injectable preparation may also be a
sterile injectable solution, suspension or emulsion in a nontoxic
parenterally acceptable diluent or solvent, for example, as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution, U.S.P.
and isotonic sodium chloride solution. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose any bland fixed oil can be employed including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid are used in the preparation of injectables.
[0115] The injectable formulations can be sterilized, for example,
by filtration through a bacterial-retaining filter, or by
incorporating sterilizing agents in the form of sterile solid
compositions which can be dissolved or dispersed in sterile water
or other sterile injectable medium prior to use.
[0116] In order to prolong the effect of a compound of the present
invention, it is often desirable to slow the absorption of the
compound from subcutaneous or intramuscular injection. This may be
accomplished by the use of a liquid suspension of crystalline or
amorphous material with poor water solubility. The rate of
absorption of the compound then depends upon its rate of
dissolution that, in turn, may depend upon crystal size and
crystalline form. Alternatively, delayed absorption of a
parenterally administered compound form is accomplished by
dissolving or suspending the compound in an oil vehicle. Injectable
depot forms are made by forming microencapsule matrices of the
compound in biodegradable polymers such as
polylactide-polyglycolide. Depending upon the ratio of compound to
polymer and the nature of the particular polymer employed, the rate
of compound release can be controlled. Examples of other
biodegradable polymers include poly(orthoesters) and
poly(anhydrides). Depot injectable formulations are also prepared
by entrapping the compound in liposomes or microemulsions that are
compatible with body tissues.
[0117] Compositions for rectal or vaginal administration are
preferably suppositories which can be prepared by mixing the
compounds of this invention with suitable non-irritating excipients
or carriers such as cocoa butter, polyethylene glycol or a
suppository wax which are solid at ambient temperature but liquid
at body temperature and therefore melt in the rectum or vaginal
cavity and release the active compound.
[0118] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium
citrate or dicalcium phosphate and/or a) fillers or extenders such
as starches, lactose, sucrose, glucose, mannitol, and silicic acid,
b) binders such as, for example, carboxymethylcellulose, alginates,
gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants
such as glycerol, d) disintegrating agents such as agar-agar,
calcium carbonate, potato or tapioca starch, alginic acid, certain
silicates, and sodium carbonate, e) solution retarding agents such
as paraffin, f) absorption accelerators such as quaternary ammonium
compounds, g) wetting agents such as, for example, cetyl alcohol
and glycerol monostearate, h) absorbents such as kaolin and
bentonite clay, and i) lubricants such as talc, calcium stearate,
magnesium stearate, solid polyethylene glycols, sodium lauryl
sulfate, and mixtures thereof. In the case of capsules, tablets and
pills, the dosage form may also comprise buffering agents.
[0119] Solid compositions of a similar type may also be employed as
fillers in soft and hard-filled gelatin capsules using such
excipients as lactose or milk sugar as well as high molecular
weight polyethylene glycols and the like. The solid dosage forms of
tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings and other
coatings well known in the pharmaceutical formulating art. They may
optionally contain opacifying agents and can also be of a
composition that they release the active ingredient(s) only, or
preferentially, in a certain part of the intestinal tract,
optionally, in a delayed manner. Examples of embedding compositions
that can be used include polymeric substances and waxes. Solid
compositions of a similar type may also be employed as fillers in
soft and hard-filled gelatin capsules using such excipients as
lactose or milk sugar as well as high molecular weight polyethylene
glycols and the like.
[0120] The active compounds can also be in microencapsulated form
with one or more excipients as noted above. The solid dosage forms
of tablets, dragees, capsules, pills, and granules can be prepared
with coatings and shells such as enteric coatings, release
controlling coatings and other coatings well known in the
pharmaceutical formulating art. In such solid dosage forms the
active compound may be admixed with at least one inert diluent such
as sucrose, lactose or starch. Such dosage forms may also comprise,
as is normal practice, additional substances other than inert
diluents, e.g., tableting lubricants and other tableting aids such
a magnesium stearate and microcrystalline cellulose. In the case of
capsules, tablets and pills, the dosage forms may also comprise
buffering agents. They may optionally contain opacifying agents and
can also be of a composition that they release the active
ingredient(s) only, or preferentially, in a certain part of the
intestinal tract, optionally, in a delayed manner. Examples of
embedding compositions that can be used include polymeric
substances and waxes.
[0121] Dosage forms for topical or transdermal administration of a
compound of this invention include ointments, pastes, creams,
lotions, gels, powders, solutions, sprays, inhalants or patches.
The active component is admixed under sterile conditions with a
pharmaceutically acceptable carrier and any needed preservatives or
buffers as may be required. Ophthalmic formulation, eardrops, and
eye drops are also contemplated as being within the scope of this
invention. Additionally, the present invention contemplates the use
of transdermal patches, which have the added advantage of providing
controlled delivery of a compound to the body. Such dosage forms
can be made by dissolving or dispensing the compound in the proper
medium. Absorption enhancers can also be used to increase the flux
of the compound across the skin. The rate can be controlled by
either providing a rate controlling membrane or by dispersing the
compound in a polymer matrix or gel.
[0122] The compositions of the present invention may be
administered orally, parenterally, by inhalation spray, topically,
rectally, nasally, buccally, vaginally or via an implanted
reservoir. The term "parenteral" as used herein includes, but is
not limited to, subcutaneous, intravenous, intramuscular,
intra-articular, intra-synovial, intrasternal, intrathecal,
intrahepatic, intralesional and intracranial injection or infusion
techniques. Preferably, the compositions are administered orally,
intraperitoneally or intravenously.
[0123] Sterile injectable forms of the compositions of this
invention may be aqueous or oleaginous suspension. These
suspensions may be formulated according to techniques known in the
art using suitable dispersing or wetting agents and suspending
agents. The sterile injectable preparation may also be a sterile
injectable solution or suspension in a non-toxic
parenterally-acceptable diluent or solvent, for example as a
solution in 1,3-butanediol. Among the acceptable vehicles and
solvents that may be employed are water, Ringer's solution and
isotonic sodium chloride solution. In addition, sterile, fixed oils
are conventionally employed as a solvent or suspending medium. For
this purpose, any bland fixed oil may be employed including
synthetic mono- or di-glycerides. Fatty acids, such as oleic acid
and its glyceride derivatives are useful in the preparation of
injectables, as are natural pharmaceutically-acceptable oils, such
as olive oil or castor oil, especially in their polyoxyethylated
versions. These oil solutions or suspensions may also contain a
long-chain alcohol diluent or dispersant, such as carboxymethyl
cellulose or similar dispersing agents which are commonly used in
the formulation of pharmaceutically acceptable dosage forms
including emulsions and suspensions. Other commonly used
surfactants, such as Tweens, Spans and other emulsifying agents or
bioavailability enhancers which are commonly used in the
manufacture of pharmaceutically acceptable solid, liquid, or other
dosage forms may also be used for the purposes of formulation.
[0124] The pharmaceutical compositions of this invention may be
orally administered in any orally acceptable dosage form including,
but not limited to, capsules, tablets, aqueous suspensions or
solutions. In the case of tablets for oral use, carriers commonly
used include, but are not limited to, lactose and corn starch.
Lubricating agents, such as magnesium stearate, are also typically
added. For oral administration in a capsule form, useful diluents
include lactose and dried cornstarch. When aqueous suspensions are
required for oral use, the active ingredient is combined with
emulsifying and suspending agents. If desired, certain sweetening,
flavoring or coloring agents may also be added.
[0125] Alternatively, the pharmaceutical compositions of this
invention may be administered in the form of suppositories for
rectal administration. These can be prepared by mixing the agent
with a suitable non-irritating excipient that is solid at room
temperature but liquid at rectal temperature and therefore will
melt in the rectum to release the drug. Such materials include, but
are not limited to, cocoa butter, beeswax and polyethylene
glycols.
[0126] The pharmaceutical compositions of this invention may also
be administered topically, especially when the target of treatment
includes areas or organs readily accessible by topical application,
including diseases of the eye, the skin, or the lower intestinal
tract. Suitable topical formulations are readily prepared for each
of these areas or organs.
[0127] Topical application for the lower intestinal tract can be
effected in a rectal suppository formulation (see above) or in a
suitable enema formulation. Topically-transdermal patches may also
be used.
[0128] For topical applications, the pharmaceutical compositions
may be formulated in a suitable ointment containing the active
component suspended or dissolved in one or more carriers. Carriers
for topical administration of the compounds of this invention
include, but are not limited to, mineral oil, liquid petrolatum,
white petrolatum, propylene glycol, polyoxyethylene,
polyoxypropylene compound, emulsifying wax and water.
Alternatively, the pharmaceutical compositions can be formulated in
a suitable lotion or cream containing the active components
suspended or dissolved in one or more pharmaceutically acceptable
carriers. Suitable carriers include, but are not limited to,
mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters
wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and
water.
[0129] For ophthalmic use, the pharmaceutical compositions may be
formulated as micronized suspensions in isotonic, pH adjusted
sterile saline, or, preferably, as solutions in isotonic, pH
adjusted sterile saline, either with or without a preservative such
as benzylalkonium chloride. Alternatively, for ophthalmic uses, the
pharmaceutical compositions may be formulated in an ointment such
as petrolatum.
[0130] The pharmaceutical compositions of this invention may also
be administered by nasal aerosol or inhalation. Such compositions
are prepared according to techniques well-known in the art of
pharmaceutical formulation and may be prepared as solutions in
saline, employing benzyl alcohol or other suitable preservatives,
absorption promoters to enhance bioavailability, fluorocarbons,
and/or other conventional solubilizing or dispersing agents.
[0131] The amount of protein kinase inhibitor that may be combined
with the carrier materials to produce a single dosage form will
vary depending upon the host treated, the particular mode of
administration. Preferably, the compositions should be formulated
so that a dosage of between 0.01-100 mg/kg body weight/day of the
inhibitor can be administered to a patient receiving these
compositions.
[0132] It should also be understood that a specific dosage and
treatment regimen for any particular patient will depend upon a
variety of factors, including the activity of the specific compound
employed, the age, body weight, general health, sex, diet, time of
administration, rate of excretion, drug combination, and the
judgment of the treating physician and the severity of the
particular disease being treated. The amount of inhibitor will also
depend upon the particular compound in the composition.
Administering with Another Agent
[0133] Depending upon the particular protein kinase-mediated
conditions to be treated or prevented, additional drugs, which are
normally administered to treat or prevent that condition, may be
administered together with the compounds of this invention.
[0134] Those additional agents may be administered separately, as
part of a multiple dosage regimen, from the protein kinase
inhibitor-containing compound or composition. Alternatively, those
agents may be part of a single dosage form, mixed together with the
protein kinase inhibitor in a single composition.
[0135] Another aspect of this invention is directed towards a
method of treating cancer in a subject in need thereof, comprising
the sequential or co-administration of a compound of this invention
or a pharmaceutically acceptable salt thereof, and one or more
additional therapeutic agents. Examples of additional therapeutic
agents include, but are not limited to, DNA-damaging agents,
anti-cancer agents, and agents that inhibit or modulates a base
excision repair protein.
[0136] Another aspect of this invention is directed towards a
method of treating cancer in a subject in need thereof, comprising
the sequential or co-administration of a compound of this invention
or a pharmaceutically acceptable salt thereof, and an anti-cancer
agent. In some embodiments, said anti-cancer agent is selected from
Platinating agents, such as Cisplatin, Oxaliplatin, Carboplatin,
Nedaplatin, or Satraplatin and other derivatives; Topo I
inhibitors, such as Camptothecin, Topotecan, irinotecan/SN38,
rubitecan and other derivatives; Topo II inhibitors, such as
Etoposide (VP-16), Daunorubicin, Doxorubicin, Mitoxantrone,
Aclarubicin, Epirubicin, Idarubicin, Amrubicin, Amsacrine,
Pirarubicin, Valrubicin, Zorubicin, Teniposide and other
derivatives; Antimetabolites, such as Folic family (Methotrexate,
Pemetrexed and relatives); Purine family (Thioguanine, Fludarabine,
Cladribine, 6-Mercaptopurine and relatives); Pyrimidine family
(Cytarabine, Gemcitabine, 5-Fluorouracil and relatives); Alkylating
agents, such as Nitrogen mustards (Cyclophosphamide, Melphalan,
Chlorambucil, mechlorethamine, Ifosfamide, and relatives);
nitrosoureas (e.g. Carmustine); Triazenes (Dacarbazine,
temozolomide); Alkyl sulphonates (e.g. Busulfan); Procarbazine and
Aziridines; Antibiotics, such as Hydroxyurea; Anthracyclines
(doxorubicin, daunorubicin, epirubicin and other derivatives);
Anthracenediones (Mitoxantrone and relatives); Streptomyces family
(Bleomycin, Mitomycin C, actinomycin) and Ultraviolet light.
[0137] Another embodiment provides a method of treating cancer in a
subject in need thereof, comprising administering a compound of
this invention with an additional therapeutic agent that inhibits
or modulates a base excision repair protein. In some embodiments,
the base excision repair protein is selected from UNG, SMUG1, MBD4,
TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3 (DNA glycosylases);
APE1, APEX2 (AP endonucleases); LIG1, LIG3 (DNA ligases I and III);
XRCC1 (LIG3 accessory); PNK, PNKP (polynucleotide kinase and
phosphatase); PARP1, PARP2 (Poly(ADP-Ribose) Polymerases); PolB,
PolG (polymerases); FEN1 (endonuclease) or Aprataxin. In other
embodiments, the base excision repair protein is selected from
PARP1, PARP2, or PolB. In yet other embodiments, the base excision
repair protein is selected from PARP1 or PARP2.
[0138] In some embodiments, the compound of this invention and the
therapeutic agent that inhibits or modulates a base excision repair
protein are further administered with an additional therapeutic
agent. In some embodiments, the additional therapeutic agent is a
DNA damaging agent selected from ionizing radiation or cisplatin.
In some embodiments, the base excision repair protein PARP1 or
PARP2. In other embodiments, the agent that inhibits or modulates
PARP1 or PARP2 is selected from Olaparib (also known as AZD2281 or
KU-0059436), Iniparib (also known as BSI-201 or SAR240550),
Veliparib (also known as ABT-888), Rucaparib (also known as
PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673, or
AZD2461.
[0139] Another embodiment provides a method of treating cancer
comprising administering a compound of this invention with a DNA
damaging agent selected from ionizing radiation or cisplatin and an
agent that inhibits or modulates PARP1 or PARP2. In some
embodiments the DNA-damaging agent is cisplatin. In other
embodiments, the DNA damaging agent is ionizing radiation. In some
embodiments the compound is VE-821. In other embodiments, the
compound is VE-822.
[0140] Another embodiment provides a method of treating cancer
comprising administering a compound of Formula I;
##STR00013##
or a pharmaceutically acceptable salt thereof, wherein the
variables are as defined herein with an agent that inhibits or
modulates PARP1 or PARP2.
[0141] In some embodiments, said method further comprises
administering a DNA damaging agent to the patient. In some
embodiments, the DNA-damaging agent is cisplatin. In other
embodiments, the DNA-damaging agent is ionizing radiation.
[0142] In some embodiments, the agent that inhibits or modulates
PARP1 or PARP2 is selected from Olaparib (also known as AZD2281 or
KU-0059436), Iniparib (also known as BSI-201 or SAR240550),
Veliparib (also known as ABT-888), Rucaparib (also known as
PF-01367338), CEP-9722, INO-1001, MK-4827, E7016, BMN673, or
AZD2461. In other embodiments, the agent that inhibits or modulates
PARP1 or PARP2 is Veliparib (also known as ABT-888) or
Rucaparib.
[0143] In some embodiments, the compound is VE-821 or VE 822.
Biological Samples
[0144] As inhibitors of ATR kinase, the compounds and compositions
of this invention are also useful in biological samples. One aspect
of the invention relates to inhibiting ATR kinase activity in a
biological sample, which method comprises contacting said
biological sample with a compound described herein or a composition
comprising said compound. The term "biological sample", as used
herein, means an in vitro or an ex vivo sample, including, without
limitation, cell cultures or extracts thereof; biopsied material
obtained from a mammal or extracts thereof; and blood, saliva,
urine, feces, semen, tears, or other body fluids or extracts
thereof. The term "compounds described herein" includes compounds
of formula I.
[0145] Inhibition of ATR kinase activity in a biological sample is
useful for a variety of purposes that are known to one of skill in
the art. Examples of such purposes include, but are not limited to,
blood transfusion, organ-transplantation, and biological specimen
storage.
Study of Protein Kinases
[0146] Another aspect of this invention relates to the study of
protein kinases in biological and pathological phenomena; the study
of intracellular signal transduction pathways mediated by such
protein kinases; and the comparative evaluation of new protein
kinase inhibitors. Examples of such uses include, but are not
limited to, biological assays such as enzyme assays and cell-based
assays.
[0147] The activity of the compounds as protein kinase inhibitors
may be assayed in vitro, in vivo or in a cell line. In vitro assays
include assays that determine inhibition of either the kinase
activity or ATPase activity of the activated kinase. Alternate in
vitro assays quantitate the ability of the inhibitor to bind to the
protein kinase and may be measured either by radiolabelling the
inhibitor prior to binding, isolating the inhibitor/kinase complex
and determining the amount of radiolabel bound, or by running a
competition experiment where new inhibitors are incubated with the
kinase bound to known radioligands. Detailed conditions for
assaying a compound utilized in this invention as an inhibitor of
ATR is set forth in the Examples below.
[0148] Another aspect of the invention provides a method for
modulating enzyme activity by contacting a compound described
herein with ATR kinase.
Methods of Treatment
[0149] In one aspect, the present invention provides a method for
treating or lessening the severity of a disease, condition, or
disorder where ATR kinase is implicated in the disease state. In
another aspect, the present invention provides a method for
treating or lessening the severity of an ATR kinase disease,
condition, or disorder where inhibition of enzymatic activity is
implicated in the treatment of the disease. In another aspect, this
invention provides a method for treating or lessening the severity
of a disease, condition, or disorder with compounds that inhibit
enzymatic activity by binding to the ATR kinase. Another aspect
provides a method for treating or lessening the severity of a
kinase disease, condition, or disorder by inhibiting enzymatic
activity of ATR kinase with an ATR kinase inhibitor.
[0150] One aspect of the invention relates to a method of
inhibiting ATR kinase activity in a patient, which method comprises
administering to the patient a compound described herein, or a
composition comprising said compound. In some embodiments, said
method is used to treat or prevent a condition selected from
proliferative and hyperproliferative diseases, such as cancer.
[0151] Another aspect of this invention provides a method for
treating, preventing, or lessening the severity of proliferative or
hyperproliferative diseases comprising administering an effective
amount of a compound, or a pharmaceutically acceptable composition
comprising a compound, to a subject in need thereof. In some
embodiments, said subject is a patient. The term "patient", as used
herein, means an animal, preferably a human.
[0152] In some embodiments, said method is used to treat or prevent
cancer. In some embodiments, said method is used to treat or
prevent a type of cancer with solid tumors. In yet another
embodiment, said cancer is selected from the following cancers:
Oral: buccal cavity, lip, tongue, mouth, pharynx; Cardiac: sarcoma
(angiosarcoma, fibrosarcoma, rhabdomyosarcoma, liposarcoma),
myxoma, rhabdomyoma, fibroma, lipoma and teratoma; Lung:
bronchogenic carcinoma (squamous cell or epidermoid,
undifferentiated small cell, undifferentiated large cell,
adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial
adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma;
Gastrointestinal: esophagus (squamous cell carcinoma, larynx,
adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma,
lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma,
insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma),
small bowel or small intestines (adenocarcinoma, lymphoma,
carcinoid tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma,
neurofibroma, fibroma), large bowel or large intestines
(adenocarcinoma, tubular adenoma, villous adenoma, hamartoma,
leiomyoma), colon, colon-rectum, colorectal; rectum, Genitourinary
tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma],
lymphoma), bladder and urethra (squamous cell carcinoma,
transitional cell carcinoma, adenocarcinoma), prostate
(adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal
carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial
cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma);
Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma,
hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma,
biliary passages; Bone: osteogenic sarcoma (osteosarcoma),
fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma,
Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma),
multiple myeloma, malignant giant cell tumor chordoma,
osteochronfroma (osteocartilaginous exostoses), benign chondroma,
chondroblastoma, chondromyxofibroma, osteoid osteoma and giant cell
tumors; Nervous system: skull (osteoma, hemangioma, granuloma,
xanthoma, osteitis deformans), meninges (meningioma,
meningiosarcoma, gliomatosis), brain (astrocytoma, medulloblastoma,
glioma, ependymoma, germinoma [pinealoma], glioblastoma multiform,
oligodendroglioma, schwannoma, retinoblastoma, congenital tumors),
spinal cord neurofibroma, meningioma, glioma, sarcoma);
Gynecological: uterus (endometrial carcinoma), cervix (cervical
carcinoma, pre-tumor cervical dysplasia), ovaries (ovarian
carcinoma [serous cystadenocarcinoma, mucinous cystadenocarcinoma,
unclassified carcinoma], granulosa-thecal cell tumors,
Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma),
vulva (squamous cell carcinoma, intraepithelial carcinoma,
adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell
carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal
rhabdomyosarcoma), fallopian tubes (carcinoma), breast; Skin:
malignant melanoma, basal cell carcinoma, squamous cell carcinoma,
Karposi's sarcoma, keratoacanthoma, moles dysplastic nevi, lipoma,
angioma, dermatofibroma, keloids, psoriasis, Thyroid gland:
papillary thyroid carcinoma, follicular thyroid carcinoma;
medullary thyroid carcinoma, multiple endocrine neoplasia type 2A,
multiple endocrine neoplasia type 2B, familial medullary thyroid
cancer, pheochromocytoma, paraganglioma; and Adrenal glands:
neuroblastoma.
[0153] In some embodiments, the cancer is selected from the cancers
described herein. In some embodiments, said cancer is lung cancer,
head and neck cancer, pancreatic cancer, gastric cancer, or brain
cancer. In other embodiments, the cancer is selected from a cancer
of the lung or the pancreas. In some embodiments, the lung cancer
is non small cell lung cancer or small cell lung cancer, such
squamous non small cell lung cancer. In other embodiments, the
cancer is selected from a cancer of the breast, such as triple
negative breast cancer.
[0154] In yet other embodiments, the cancer is selected from
non-small cell lung cancer, small cell lung cancer, pancreatic
cancer, biliary tract cancer, head and neck cancer, bladder cancer,
colorectal cancer, glioblastoma, esophageal cancer, breast cancer,
hepatocellular carcinoma, or ovarian cancer.
[0155] In certain embodiments, an "effective amount" of the
compound or pharmaceutically acceptable composition is that amount
effective in order to treat said disease. The compounds and
compositions, according to the method of the present invention, may
be administered using any amount and any route of administration
effective for treating or lessening the severity of said
disease.
[0156] One aspect provides a method for inhibiting ATR in a patient
comprising administering a compound described herein as described
herein. Another embodiment provides a method of treating cancer
comprising administering to a patient a compound described herein,
wherein the variables are as defined herein.
[0157] Some embodiments comprising administering to said patient an
additional therapeutic agent selected from a DNA-damaging agent;
wherein said additional therapeutic agent is appropriate for the
disease being treated; and said additional therapeutic agent is
administered together with said compound as a single dosage form or
separately from said compound as part of a multiple dosage
form.
[0158] In some embodiments, said DNA-damaging agent is selected
from ionizing radiation, radiomimetic neocarzinostatin, a
platinating agent, a Topo I inhibitor, a Topo II inhibitor, an
antimetabolite, an alkylating agent, an alkyl sulphonates, an
antimetabolite, or an antibiotic. In other embodiments, said
DNA-damaging agent is selected from ionizing radiation, a
platinating agent, a Topo I inhibitor, a Topo II inhibitor, or an
antibiotic.
[0159] Examples of Platinating agents include Cisplatin,
Oxaliplatin, Carboplatin, Nedaplatin, Satraplatin and other
derivatives. Other platinating agents include Lobaplatin, and
Triplatin. Other platinating agents include Tetranitrate,
Picoplatin, Satraplatin, ProLindac and Aroplatin.
[0160] Examples of Topo I inhibitor include Camptothecin,
Topotecan, irinotecan/SN38, rubitecan and other derivatives. Other
Topo I inhibitors include Belotecan.
[0161] Examples of Topo II inhibitors include Etoposide,
Daunorubicin, Doxorubicin, Mitoxantrone, Aclarubicin, Epirubicin,
Idarubicin, Amrubicin, Amsacrine, Pirarubicin, Valrubicin,
Zorubicin and Teniposide.
[0162] Examples of Antimetabolites include members of the Folic
family, Purine family (purine antagonists), or Pyrimidine family
(pyrimidine antagonists). Examples of the Folic family include
methotrexate, pemetrexed and relatives; examples of the Purine
family include Thioguanine, Fludarabine, Cladribine,
6-Mercaptopurine, and relatives; examples of the Pyrimidine family
include Cytarabine, gemcitabine, 5-Fluorouracil (5FU) and
relatives.
[0163] Some other specific examples of antimetabolites include
Aminopterin, Methotrexate, Pemetrexed, Raltitrexed, Pentostatin,
Cladribine, Clofarabine, Fludarabine, Thioguanine, Mercaptopurine,
Fluorouracil, Capecitabine, Tegafur, Carmofur, Floxuridine,
Cytarabine, Gemcitabine, Azacitidine and Hydroxyurea.
[0164] Examples of alkylating agents include Nitrogen mustards,
Triazenes, alkyl sulphonates, Procarbazine and Aziridines. Examples
of Nitrogen mustards include Cyclophosphamide, Melphalan,
Chlorambucil and relatives; examples of nitrosoureas include
Carmustine; examples of triazenes include Dacarbazine and
temozolomide; examples of alkyl sulphonates include Busulfan.
[0165] Other specific examples of alkylating agents include
Mechlorethamine, Cyclophosphamide, Ifosfamide, Trofosfamide,
Chlorambucil, Melphalan, Prednimustine, Bendamustine, Uramustine,
Estramustine, Carmustine, Lomustine, Semustine, Fotemustine,
Nimustine, Ranimustine, Streptozocin, Busulfan, Mannosulfan,
Treosulfan, Carboquone, ThioTEPA, Triaziquone, Triethylenemelamine,
Procarbazine, Dacarbazine, Temozolomide, Altretamine, Mitobronitol,
Actinomycin, Bleomycin, Mitomycin and Plicamycin.
[0166] Examples of antibiotics include Mitomycin, Hydroxyurea;
Anthracyclines, Anthracenediones, Streptomyces family. Examples of
Anthracyclines include doxorubicin, daunorubicin, epirubicin and
other derivatives; examples of Anthracenediones include
Mitoxantrone and relatives; examples of Streptomyces family include
Bleomycin, Mitomycin C, and actinomycin.
[0167] In certain embodiments, said platinating agent is Cisplatin
or Oxaliplatin; said Topo I inhibitor is Camptothecin; said Topo II
inhibitor is Etoposide; and said antibiotic is Mitomycin. In other
embodiments, said platinating agent is selected from Cisplatin,
Oxaliplatin, Carboplatin, Nedaplatin, or Satraplatin; said Topo I
inhibitor is selected from Camptothecin, Topotecan,
irinotecan/SN38, rubitecan; said Topo II inhibitor is selected from
Etoposide; said antimetabolite is selected from a member of the
Folic Family, the Purine Family, or the Pyrimidine Family; said
alkylating agent is selected from nitrogen mustards, nitrosoureas,
triazenes, alkyl sulfonates, Procarbazine, or aziridines; and said
antibiotic is selected from Hydroxyurea, Anthracyclines,
Anthracenediones, or Streptomyces family.
[0168] In some embodiments, the additional therapeutic agent is
ionizing radiation. In other embodiments, the additional
therapeutic agent is Cisplatin or Carboplatin. In yet other
embodiments, the additional therapeutic agent is Etoposide. In yet
other embodiments, the additional therapeutic agent is
Temozolomide.
[0169] In certain embodiments, the additional therapeutic agent is
selected from one or more of the following: Cisplatin, Carboplatin,
gemcitabine, Etoposide, Temozolomide, or ionizing radiation.
[0170] In other embodiments, the additional therapeutic agents are
selected from one or more of the following: gemcitabine, cisplatin
or carboplatin, and etoposide. In yet other embodiments, the
additional therapeutic agents are selected from one or more of the
following: cisplatin or carboplatin, etoposide, and ionizing
radiation. In some embodiments, the cancer is lung cancer. In some
embodiments, the lung cancer is non-small cell lung cancer or small
cell lung cancer.
[0171] Another embodiment provides a method of treating small cell
lung cancer comprising administering to a patient a compound of the
invention in combination with cisplatin and etoposide.
[0172] Another embodiment provides a method of treating non-small
cell lung cancer comprising administering to a patient a compound
of Formula I in combination with gemcitabine and cisplatin. In some
embodiments, the non-small cell lung cancer is squamous non-small
cell lung cancer.
[0173] Another embodiment provides a method of treating breast
cancer comprising administering to a patient a compound of Formula
I in combination with cisplatin. In some embodiments, the breast
cancer is triple negative breast cancer.
[0174] In some embodiments, the compound is a compound of Formula
I. In other embodiments, the compound is VE-821. In other
embodiments, the compound is VE-822.
[0175] Another embodiment provides methods for treating pancreatic
cancer by administering a compound described herein in combination
with another known pancreatic cancer treatment. One aspect of the
invention includes administering a compound described herein in
combination with gemcitabine. In some embodiments, the pancreatic
cancer comprises one of the following cell lines: PSN-1, MiaPaCa-2
or Panc-1. According to another aspect, the cancer comprises one of
the following primary tumor lines: Panc-M or MRC5.
[0176] Another embodiment provides a method of treating breast
cancer with a compound described herein in combination with a
platinating agent. In some embodiments, the breast cancer is triple
negative breast cancer. In other embodiments, the platinating agent
is cisplatin. Another embodiment provides a method of treating
triple negative breast cancer with a compound described herein in
combination with cisplatin.
[0177] Another embodiment provides a method of treating small cell
lung cancer with a compound described herein in combination with
cisplatin and etoposide.
[0178] Another embodiment provides a method of treating non-small
cell lung cancer with a compound described herein in combination
with cisplatin and gemcitabine. In some embodiments, the non-small
cell lung cancer is squamous non-small cell lung cancer. In some
embodiments, the compound is a compound of Formula I. In other
embodiments, the compound is VE-822.
[0179] Another aspect of the invention includes administering a
compound described herein in combination with radiation therapy.
Yet another aspect provides a method of abolishing
radiation-induced G2/M checkpoint by administering a compound
described herein in combination with radiation treatment.
[0180] Another aspect provides a method of treating pancreatic
cancer by administering to pancreatic cancer cells a compound
described herein in combination with one or more cancer therapies.
In some embodiments, the compound is combined with chemoradiation,
chemotherapy, and/or radiation therapy. As would be understood by
one of skill in the art, chemoradiation refers to a treatment
regime that includes both chemotherapy (such as gemcitabine) and
radiation. In some embodiments, the chemotherapy is
gemcitabine.
[0181] Yet another aspect provides a method of increasing the
sensitivity of pancreatic cancer cells to a cancer therapy selected
from gemcitabine or radiation therapy by administering a compound
described herein in combination with the cancer therapy.
[0182] In some embodiments, the cancer therapy is gemcitabine. In
other embodiments, the cancer therapy is radiation therapy. In yet
another embodiment the cancer therapy is chemoradiation.
[0183] Another aspect provides a method of inhibiting
phosphorylation of Chk1 (Ser 345) in a pancreatic cancer cell
comprising administering a compound described herein after
treatment with gemcitabine (100 nM) and/or radiation (6 Gy) to a
pancreatic cancer cell.
[0184] Another aspect provides method of radiosensitizing hypoxic
PSN-1, MiaPaCa-2 or PancM tumor cells by administering a compound
described herein to the tumor cell in combination with radiation
therapy.
[0185] Yet another aspect provides a method of sensitizing hypoxic
PSN-1, MiaPaCa-2 or PancM tumor cells by administering a compound
described herein to the tumor cell in combination with
gemcitabine.
[0186] Another aspect provides a method of sensitizing PSN-1 and
MiaPaCa-2 tumor cells to chemoradiation by administering a compound
described herein to the tumor cells in combination with
chemoradiation.
[0187] Another aspect provides a method of disrupting
damage-induced cell cycle checkpoints by administering a compound
described herein in combination with radiation therapy to a
pancreatic cancer cell.
[0188] Another aspect provides a method of inhibiting repair of DNA
damage by homologous recombination in a pancreatic cancer cell by
administering a compound described herein in combination with one
or more of the following treatments: chemoradiation, chemotherapy,
and radiation therapy.
[0189] In some embodiments, the chemotherapy is gemcitabine.
[0190] Another aspect provides a method of inhibiting repair of DNA
damage by homologous recombination in a pancreatic cancer cell by
administering a compound described herein in combination with
gemcitabine and radiation therapy.
[0191] In some embodiments, the pancreatic cancer cells are derived
from a pancreatic cell line selected from PSN-1, MiaPaCa-2 or
Panc-1.
[0192] In other embodiments, the pancreatic cancer cells are in a
cancer patient.
[0193] Another aspect of the invention provides a method of
treating non-small cell lung cancer comprising administering to a
patient a compound described herein in combination with one or more
of the following additional therapeutic agents: Cisplatin or
Carboplatin, Etoposide, and ionizing radiation. Some embodiments
comprise administering to a patient a compound described herein in
combination with Cisplatin or Carboplatin, Etoposide, and ionizing
radiation. In some embodiments the combination is Cisplatin,
Etoposide, and ionizing radiation. In other embodiments the
combination is Carboplatin, Etoposide, and ionizing radiation.
[0194] Another embodiment provides a method of promoting cell death
in cancer cells comprising administering to a patient a compound
described herein, or a composition comprising said compound.
[0195] Yet another embodiment provides a method of preventing cell
repair of DNA damage in cancer cells comprising administering to a
patient a compound described herein, or a composition comprising
said compound. Yet another embodiment provides a method of
preventing cell repair caused by of DNA damage in cancer cells
comprising administering to a patient a compound of formula I, or a
composition comprising said compound.
[0196] Another embodiment provides a method of sensitizing cells to
DNA damaging agents comprising administering to a patient a
compound described herein, or a composition comprising said
compound.
[0197] In some embodiments, the method is used on a cancer cell
having defects in the ATM signaling cascade. In some embodiments,
said defect is altered expression or activity of one or more of the
following: ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX,
MCPH1/BRIT1, CTIP, or SMC1. In other embodiments, said defect is
altered expression or activity of one or more of the following:
ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1 or H2AX. In another
embodiment, the cell is a cancer cell expressing DNA damaging
oncogenes. In some embodiments, said cancer cell has altered
expression or activity of one or more of the following: K-Ras,
N-Ras, H-Ras, Raf, Myc, Mos, E2F, Cdc25A, CDC4, CDK2, Cyclin E,
Cyclin A and Rb.
[0198] According to another embodiment, the method is used on a
cancer, cancer cell, or cell has a defect in a protein involved in
base excision repair ("base excision repair protein"). There are
many methods known in the art for determining whether a tumor has a
defect in base excision repair. For example, sequencing of either
the genomic DNA or mRNA products of each base excision repair gene
(e.g., UNG, PARP1, or LIG1) can be performed on a sample of the
tumor to establish whether mutations expected to modulate the
function or expression of the gene product are present (Wang et
al., Cancer Research 52:4824 (1992)). In addition to the mutational
inactivation, tumor cells can modulate a DNA repair gene by
hypermethylating its promoter region, leading to reduced gene
expression. This is most commonly assessed using
methylation-specific polymerase chain reaction (PCR) to quantify
methylation levels on the promoters of base excision repair genes
of interest. Analysis of base excision repair gene promoter
methylation is available commercially
(http://www.sabiosciences.com/dna_methylation_product/HTML/MEAH-421A.html-
).
[0199] Finally, the expression levels of base excision repair genes
can be assessed by directly quantifying levels of the mRNA and
protein products of each gene using standard techniques such as
quantitative reverse transcriptase-coupled polymerase chain
reaction (RT-PCR) and immunohistochemistry (IHC), respectively
(Shinmura et al., Carcinogenesis 25: 2311 (2004); Shinmura et al.,
Journal of Pathology 225:414 (2011)).
[0200] In some embodiments, the base excision repair protein is
UNG, SMUG1, MBD4, TDG, OGG1, MYH, NTH1, MPG, NEIL1, NEIL2, NEIL3
(DNA glycosylases); APE1, APEX2 (AP endonucleases); LIG1, LIG3 (DNA
ligases I and III); XRCC1 (LIG3 accessory); PNK, PNKP
(polynucleotide kinase and phosphatase); PARP1, PARP2
(Poly(ADP-Ribose) Polymerases); PolB, PolG (polymerases); FEN1
(endonuclease) or Aprataxin.
[0201] In some embodiments, the base excision repair protein is
PARP1, PARP2, or PolB. In other embodiments, the base excision
repair protein is PARP1 or PARP2.
[0202] The methods described above (gene sequence, promoter
methylation and mRNA expression) may also be used to characterize
the status (e.g., expression or mutation) of other genes or
proteins of interesting, such DNA-damaging oncogenes expressed by a
tumor or defects in the ATM signaling cascade of a cell.
[0203] Yet another embodiment provides use of a compound described
herein as a radio-sensitizer or a chemo-sensitizer.
[0204] Yet other embodiment provides use of a compound of formula I
as a single agent (monotherapy) for treating cancer. In some
embodiments, the compounds of formula I are used for treating
patients having cancer with a DNA-damage response (DDR) defect. In
other embodiments, said defect is a mutation or loss of ATM, p53,
CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, or H2AX. According to
another embodiment, the method is used on a cancer, cancer cell, or
cell expressing DNA damaging oncogenes.
Compounds and Compositions for Use
[0205] One embodiment provides a compound or composition as
described herein for use as a radio-sensitizer or a
chemo-sensitizer. Another embodiment provides a compound or
composition as described herein for use as a single agent
(monotherapy) for treating cancer.
[0206] Another embodiment provides a compound or composition as
described herein for treating patients having cancer with a
DNA-damage response (DDR) defect. In some embodiments, said defect
is a mutation or loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1,
MDC1, or H2AX. In other embodiments, said defect is a mutation or
loss of ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX,
MCPH1/BRIT1, CTIP, or SMC1.
[0207] Another embodiment provides compounds or compositions
described herein for treating cancer. In some embodiments, the
compound or composition is further combined with an additional
therapeutic agent described herein. In some embodiments, the
compound or composition is further combined with a DNA damaging
agent described herein.
[0208] In some embodiments, the cancer has a defect in a pathway
described herein.
Manufacture of Medicaments
[0209] One embodiment provides the use of a compound or composition
described herein for the manufacture of a medicament for use as a
radio-sensitizer or a chemo-sensitizer. Another embodiment provides
the use of a compound or composition described herein for the
manufacture of a medicament for the manufacture of a medicament for
use as a single agent (monotherapy) for treating cancer.
[0210] Yet another embodiment provides the use of a compound or
composition described herein for the manufacture of a medicament
for the manufacture of a medicament for treating patients having
cancer with a DNA-damage response (DDR) defect.
[0211] In some embodiments, said defect is a mutation or loss of
ATM, p53, CHK2, MRE11, RAD50, NBS1, 53BP1, MDC1, or H2AX. In other
embodiments, said defect is a mutation or loss of ATM, p53, CHK2,
MRE11, RAD50, NBS1, 53BP1, MDC1, H2AX, MCPH1/BRIT1, CTIP, or
SMC1.
[0212] Another embodiment provides the use of a compound or
composition described herein for the manufacture of a medicament
for treating cancer. In some embodiments, the compound or
composition is combined with an additional therapeutic agent, such
as a DNA damaging agent, described herein. In another embodiment,
the cancer has a defect in a pathway described herein.
SCHEMES AND EXAMPLES
[0213] The compounds of the disclosure may be prepared according to
steps generally known to those of ordinary skill in the art. More
specifically, the compounds may be prepared according to the
schemes and examples described in WO 2010/071837, the contents of
which are hereby incorporated by reference. Those compounds may be
analyzed by known methods, including but not limited to LCMS
(liquid chromatography mass spectrometry) and NMR (nuclear magnetic
resonance). The following generic schemes illustrate how to prepare
the compounds of the present disclosure. Any examples are for the
purpose of illustration only and are not to be construed as
limiting the scope of the invention in any way. .sup.1H-NMR spectra
were recorded at 400 MHz using a Bruker DPX 400 instrument. Mass
spec. samples were analyzed on a MicroMass Quattro Micro mass
spectrometer operated in single MS mode with electrospray
ionization.
##STR00014##
[0214] Cyclic amides compounds of the present disclosure wherein
-L-R.sup.1 is an aromatic amide can be prepared according to
methods similar to the one depicted in Scheme I-A1: Commercially
available ester 1 is reacted with a boronic acid under Suzuki
conditions to give intermediate 2. The carboxylic acid group is
engaged in a coupling reaction with an amine to lead to cyclic
amide compounds of the Formula IA-1.
##STR00015##
[0215] Alternatively, compounds of the present disclosure wherein
-L-R.sup.1 is an aromatic amide can be prepared according to
methods similar to the one depicted in Scheme I-A2, a variation of
the synthetic sequence depicted in scheme I-A1 which consists in
starting from methyl ester 1. Ester 1 is transformed into
carboxylic acid 3 which is engaged in a coupling reaction with an
amine to give amide 4. This is reacted with a boronic acid under
Suzuki conditions to lead to compounds of formula IA-2.
##STR00016##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0216] Compounds of the present disclosure where Ring A is a
1,3,4-oxadiazole can be prepared according to methods similar to
the one depicted in Scheme I-B1: methyl ester 3 is reacted with a
boronic acid under Suzuki conditions to give intermediate 8. The
carboxylic acid in 8 is then engaged into a coupling reaction with
an hydrazide (X.dbd.O) or thiohydrazide (X.dbd.S) to form 9.
Finally, the acylhydrazide in 9 undergoes a cyclodehydration to
lead to compounds of the present disclosure (formula I in Scheme
I-B1). Transformation of intermediate 8 into compounds of formula
IB-1 has also been performed in a one-pot procedure using reagents
serving two purposes (coupling and cyclodehydration).
##STR00017##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0217] Alternatively, compounds of the present disclosure where
Ring A is a 1,3,4-oxadiazole can be prepared according to methods
similar to the one depicted in Scheme I-B2, a variation of the
synthetic sequence depicted in scheme I-B1. The hydrazide 5 is
engaged in a coupling reaction with a carboxylic acid functional
group to form intermediate 9 (X.dbd.O). As in scheme I-B1 the
acylhydrazide then undergoes a cyclodehydration to lead to
compounds of formula IB-2. When R5 is a moiety bound to the
oxadiazole ring through a C--N bond, then an thioisocyanate can be
used to generate intermediate 9 (X.dbd.S); the thioacylhydrazide
then undergoes a cyclodehydration to lead to compounds of formula
IB-2.
##STR00018##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0218] Alternatively, compounds of the present disclosure where
Ring A is 1,3,4-oxadiazole can be prepared according to methods
similar to the one depicted in Scheme I-B3: the R functional group
in 10 or 6 (acid and hydrazide respectively, both prepared from
methyl ester 3 through hydrolysis and hydrazinolysis respectively)
are engaged into coupling with a suitable partner
(R.sub.5CXNHNH.sub.2 when starting from 10;
R.sub.5COOH/R.sub.5.dbd..dbd.S when starting from 6) to form
acylhydrazide intermediate 11. Subsequent cyclodehydration leads to
the compound 12 where the 1,3,4-oxadiazole ring has been
constructed. Transformation of starting point 10 or 6 into
intermediate 12 has also been performed in a one-pot procedure
using reagents serving two purposes (coupling and
cyclodehydration). The bromo handle in oxadiazole 12 is then
reacted with a boronic acid under Suzuki conditions to give
compounds of formula IB-3. When R group in Formula IB-3 contains a
carboxylic acid moiety, it can be further transformed (eg into an
amide) using conditions known in the art.
##STR00019##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0219] Compounds of the present disclosure where Ring A is a
1,2,4-oxadiazole can be prepared according to methods similar to
the one depicted in Scheme I-C1: nitrile 2 reacts with
hydroxylamine to give intermediate 13. The hydroxy group in 13
reacts with acid chlorides to lead to intermediate 14 which
undergoes cyclodehydration to afford compounds of formula IC-1.
##STR00020##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0220] Alternatively, compounds of the present disclosure where
Ring A is a 1,2,4-oxadiazole can be prepared according to methods
similar to the one depicted in Scheme I-C2: Commercially available
nitrile 1 reacts with hydroxylamine to give intermediate 15. The
hydroxy group in 15 reacts with acid chlorides to lead to
intermediate 16 which undergoes cyclodehydration to afford
intermediate 17. The bromo handle in 17 is then used to perform a
Suzuki reaction with a boronic acid coupling partner to give
compounds of formula IC-2. When R group in Formula IC-2 contains a
carboxylic acid moiety, it can be further transformed (eg into an
amide) using conditions known in the art.
##STR00021##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0221] Compounds of the present disclosure where Ring A is a
1,3,4-thiadiazole can be prepared according to methods similar to
the one depicted in Scheme I-D1: methyl ester 3 is reacted with a
boronic acid under Suzuki conditions to give intermediate 8. The
carboxylic acid in 8 is then engaged into a coupling reaction with
a thiohydrazide to form 18. Finally, the thioacylhydrazide in 18
undergoes a cyclodehydration to lead to compounds of Formula ID-1.
Transformation of intermediate 8 into compounds of Formula I-D1 can
be performed in a one-pot procedure using reagents serving two
purposes (coupling and cyclodehydration)
##STR00022##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0222] Alternatively, compounds of the present disclosure where
Ring A is 1,3,4-thiadiazole can be prepared according to methods
similar to the one depicted in Scheme I-D2: the acid functional
group in 10 is engaged into coupling with a suitable partner
(R.sub.5CSNHNH.sub.2) to form the thioacylhydrazide intermediate
19. Subsequent cyclodehydration leads to the compound 20 where the
1,3,4-thiadiazole ring has been constructed. Transformation of
starting point 10 into 20 has been performed in a one-pot procedure
using reagents serving two purposes (coupling and
cyclodehydration). The bromo handle in thiadiazole 20 is then
reacted with a boronic acid under Suzuki conditions to give
compounds of formula I-D2. When R group in Formula I-D2 contains a
carboxylic acid moiety, it can be further transformed (eg into an
amide) using conditions known in the art.
##STR00023##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0223] Compounds of the present disclosure where Ring A is an
isoxazole can be prepared according to methods similar to the one
depicted in Scheme I-E1: Commercially available 2-amino-3,5-dibromo
pyrazine 21 undergoes a Sonogashira coupling with TMS-acetylene to
give intermediate 22, the amino group of which can be fully
protected as the diBoc species 23. A Suzuki coupling with the
remaining bromo handle, with concommitant TMS deprotection affords
intermediate 24. The alkyne 24 finally reacts in a
cyclocondensation with N-hydroxyaroyl chloride to furnish compounds
of Formula I-E1.
##STR00024##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0224] Alternatively, compounds of the present disclosure where
Ring A is an isoxazole can be prepared according to methods similar
to the one depicted in Scheme I-E2: The TMS-protected intermediate
23, described in scheme I-E1 can be deprotected to reveal the
alkyne compound 25. The alkyne 25 reacts in a cyclocondensation
with N-hydroxyaroyl chloride to furnish intermediate 26 where the
isoxazole ring has been constructed. The bromo handle in isoxazole
26 is then reacted with a boronic acid under Suzuki conditions to
give compounds 27. A final deprotection of N-protecting groups in
27 can reveal compounds of Formula I. When R group in Formula I-E2
contains a carboxylic acid moiety, it can be further transformed
(eg into an amide) using conditions known in the art.
##STR00025##
[0225] Compounds of Formula I-E3 can be made according to the steps
outlined in Scheme I-E3. Reductive amination between compound 1 and
an amine (e.g., J.sup.5p1-NH.sub.2), leads to compound 2.
Conditions for reductive amination include, for example, combining
compound 1 with J.sup.5p1-NH.sub.2 in methanol to form an imine
intermediate which is reduced with NaBH.sub.4 to form compound 2.
Compound 2 can then be protected with nitrogen protecting groups
known to those skilled in the art. For example, compound 2 can be
combined with (Boc).sub.2O and Et.sub.3N in DCM to form compound 3
(wherein PG=Boc).
[0226] Compound 3 can be combined with hydroxylamine hydrochloride
under suitable oxime formation conditions to form compound 4.
Suitable oxime formation conditions include either a one-step
procedure or a two-step procedure. The one-step procedure comprises
stirring 1 equivalent of compound 3 with a 1.1 equivalents of
NH.sub.2OH.HCl in a 10:1 v/v mixture of THF/water. The two step
procedure comprises first deprotecting the ketal group of compound
3 into an aldehyde under suitable deprotection conditions, and then
forming an oxime under suitable two-step oxime formation conditions
to form compound 4.
[0227] Compound 4 can be combined with the BOC-protected
aminopyrazine shown in Scheme I-E3 under suitable isoxazole
formation conditions to form compound 5. Compound 4 is transformed
and engaged in a [3+2] cycloaddition to form the isoxazole 5. This
transformation can be conducted in one pot but requires two
distinct steps. The first step is an oxidation of the oxime
functional group into a nitrone, or a similar intermediate with the
same degree of oxidation, for example a chlorooxime. This reactive
species then reacts with an alkyne in a [3+2] cycloaddition to form
the isoxazole adduct.
[0228] Finally, compound 5 undergoes a metal-assisted coupling
reaction to form compound 6. For example, compound 5 can be
combined with a boronic acid under Suzuki cross-coupling conditions
to form the compound of formula 6.
##STR00026##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0229] Alternatively, compounds of the present disclosure where
Ring A is a 1,2,4-triazole can be prepared according to methods
similar to the one depicted in Scheme I-F1 starting from methyl
ester 3. Ester 3 is reacted with a boronic acid under Suzuki
conditions to give intermediate 4. When R group contains a
carboxylic acid moiety, it can be further transformed at this stage
(eg into an amide) using conditions known in the art. The methyl
ester group in 4 is then transformed into an hydrazide by reaction
with hydrazine to give 5. Finally, the hydrazide group in 5 is
engaged in a coupling reaction with a nitrile and subsequently
undergoes a cyclodehydration to lead to compounds of Formula
I-F1.
##STR00027##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0230] Alternatively, compounds of the present disclosure where
Ring A is a 1,2,4-triazole can be prepared according to methods
similar to the one depicted in Scheme I-F2: the R functional group
in 1 or 3 (nitrile and methyl ester respectively) are engaged into
coupling (after appropriate transformation of 3 into hydrazide 6)
with a suitable coupling partner (R.sub.5CONHNH.sub.2 when starting
from 1; R.sub.5CN if using 6). Subsequent cyclodehydration leads to
the intermediate 7 where the 1,2,4-triazole ring has been
constructed. The bromo handle in triazole 7 is then reacted with a
boronic acid under Suzuki conditions to give compounds of formula
I-F2. When R group in Formula I-F2 contains a carboxylic acid
moiety, it can be further transformed (eg into an amide) using
conditions known in the art.
##STR00028##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0231] Benzoxazole compounds of Formula VI can be prepared
according to methods similar to the one depicted in Scheme I-G1:
Commercially available nitrile 1 is reacted with a amino phenol to
give the benzoxazole which is then reacted with a boronic acid
under Suzuki conditions to give compounds of the Formula I-G1.
##STR00029##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0232] Benzothiazole compounds of Formula VI can be prepared
according to methods similar to the one depicted in Scheme I-H1:
Commercially available nitrile 1 is reacted with a
aminobenzenethiol to give the benzothiazole which is then reacted
with a boronic acid under Suzuki conditions to give compounds of
the Formula I-H1.
##STR00030##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0233] Alternatively, benzothiazole compounds of Formula VI can be
prepared according to Scheme I-H2; methyl ester 3 is reacted with a
boronic acid under Suzuki conditions to give intermediate 8.
Cyclisation of intermediate 8 with an amino benzenethiol will lead
to compounds of the Formula I-H2.
##STR00031##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0234] Benzimidazole compounds of Formula I can be prepared
according to methods similar to the one depicted in Scheme I-I1:
methyl ester 3 is reacted with a boronic acid under Suzuki
conditions to give intermediate 8. Cyclisation of intermediate 8
with a benzene 1,2-diamine will lead to compounds of the Formula
I-I1.
##STR00032##
wherein R is -(L-NR.sup.1R.sup.2).sub.p or -(J.sub.2).sub.q
[0235] Alternatively, benzimidazole compounds of Formula I can be
prepared according to methods similar to the one depicted in Scheme
I-I2: Reaction of the acid functional group of 3 is reacted with a
benzene 1,2-diamine to give the benzimidazole intermediate 9.
Intermediate 9 is then reacted with a boronic acid under Suzuki
conditions to give compounds of the Formula I-I2.
Example 2
Cellular ATR Inhibition Assay
[0236] Compounds can be screened for their ability to inhibit
intracellular ATR using an immunofluorescence microscopy assay to
detect phosphorylation of the ATR substrate histone H2AX in
hydroxyurea treated cells. HT29 cells are plated at 14,000 cells
per well in 96-well black imaging plates (BD 353219) in McCoy's 5A
media (Sigma M8403) supplemented with 10% foetal bovine serum (JRH
Biosciences 12003), Penicillin/Streptomycin solution diluted 1:100
(Sigma P7539), and 2 mM L-glutamine (Sigma G7513), and allowed to
adhere overnight at 37.degree. C. in 5% CO.sub.2. Compounds are
then added to the cell media from a final concentration of 25 .mu.M
in 3-fold serial dilutions and the cells are incubated at
37.degree. C. in 5% CO.sub.2. After 15 min, hydroxyurea (Sigma
H8627) is added to a final concentration of 2 mM.
[0237] After 45 min of treatment with hydroxyurea, the cells are
washed in PBS, fixed for 10 min in 4% formaldehyde diluted in PBS
(Polysciences Inc 18814), washed in 0.2% Tween-20 in PBS (wash
buffer), and permeabilised for 10 min in 0.5% Triton X-100 in PBS,
all at room temperature. The cells are then washed once in wash
buffer and blocked for 30 min at room temperature in 10% goat serum
(Sigma G9023) diluted in wash buffer (block buffer). To detect H2AX
phosphorylation levels, the cells are then incubated for 1 h at
room temperature in primary antibody (mouse monoclonal
anti-phosphorylated histone H2AX Ser139 antibody; Upstate 05-636)
diluted 1:250 in block buffer. The cells are then washed five times
in wash buffer before incubation for 1 h at room temperature in the
dark in a mixture of secondary antibody (goat anti-mouse Alexa
Fluor 488 conjugated antibody; Invitrogen A11029) and Hoechst stain
(Invitrogen H3570); diluted 1:500 and 1:5000, respectively, in wash
buffer. The cells are then washed five times in wash buffer and
finally 100 ul PBS is added to each well before imaging.
[0238] Cells are imaged for Alexa Fluor 488 and Hoechst intensity
using the BD Pathway 855 Bioimager and Attovision software (BD
Biosciences, Version 1.6/855) to quantify phosphorylated H2AX
Ser139 and DNA staining, respectively. The percentage of
phosphorylated H2AX-positive nuclei in a montage of 9 images at
20.times. magnification is then calculated for each well using BD
Image Data Explorer software (BD Biosciences Version 2.2.15).
Phosphorylated H2AX-positive nuclei are defined as Hoechst-positive
regions of interest containing Alexa Fluor 488 intensity at
1.75-fold the average Alexa Fluor 488 intensity in cells not
treated with hydroxyurea. The percentage of H2AX positive nuclei is
finally plotted against concentration for each compound and IC50s
for intracellular ATR inhibition are determined using Prism
software (GraphPad Prism version 3.0cx for Macintosh, GraphPad
Software, San Diego Calif., USA).
[0239] The compounds described herein can also be tested according
to other methods known in the art (see Sarkaria et al, "Inhibition
of ATM and ATR Kinase Activities by the Radiosensitizing Agent,
Caffeine: Cancer Research 59: 4375-5382 (1999); Hickson et al,
"Identification and Characterization of a Novel and Specific
Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM" Cancer
Research 64: 9152-9159 (2004); Kim et al, "Substrate Specificities
and Identification of Putative Substrates of ATM Kinase Family
Members" The Journal of Biological Chemistry, 274(53): 37538-37543
(1999); and Chiang et al, "Determination of the catalytic
activities of mTOR and other members of the
phosphoinositide-3-kinase-related kinase family" Methods Mol. Biol.
281:125-41 (2004)).
Example 3
ATR Inhibition Assay
[0240] Compounds can be screened for their ability to inhibit ATR
kinase using a radioactive-phosphate incorporation assay. Assays
are carried out in a mixture of 50 mM Tris/HCl (pH 7.5), 10 mM
MgCl.sub.2 and 1 mM DTT. Final substrate concentrations are 10
.mu.M [.gamma.-33P]ATP (3 mCi 33P ATP/mmol ATP, Perkin Elmer) and
800 .mu.M target peptide (ASELPASQPQPFSAKKK).
[0241] Assays are carried out at 25.degree. C. in the presence of 5
nM full-length ATR. An assay stock buffer solution is prepared
containing all of the reagents listed above, with the exception of
ATP and the test compound of interest. 13.5 .mu.L of the stock
solution is placed in a 96 well plate followed by addition of 2
.mu.L of DMSO stock containing serial dilutions of the test
compound (typically starting from a final concentration of 15 .mu.M
with 3-fold serial dilutions) in duplicate (final DMSO
concentration 7%). The plate is pre-incubated for 10 minutes at
25.degree. C. and the reaction initiated by addition of 15 .mu.L
[.gamma.-.sup.33P]ATP (final concentration 10 .mu.M).
[0242] The reaction is stopped after 24 hours by the addition of 30
.mu.L 0.1M phosphoric acid containing 2 mM ATP. A multiscreen
phosphocellulose filter 96-well plate (Millipore, Cat no.
MAPHN0B50) is pretreated with 100 .mu.L 0.2M phosphoric acid prior
to the addition of 45 .mu.L of the stopped assay mixture. The plate
is washed with 5.times.200 .mu.L 0.2M phosphoric acid. After
drying, 100 .mu.L Optiphase `SuperMix` liquid scintillation
cocktail (Perkin Elmer) is added to the well prior to scintillation
counting (1450 Microbeta Liquid Scintillation Counter, Wallac).
[0243] After removing mean background values for all of the data
points, Ki(app) data are calculated from non-linear regression
analysis of the initial rate data using the Prism software package
(GraphPad Prism version 3.0cx for Macintosh, GraphPad Software, San
Diego Calif., USA).
Example 4
Cisplatin Sensitization Assay
[0244] Compounds can be screened for their ability to sensitize
HCT116 colorectal cancer cells to Cisplatin using a 96 h cell
viability (MTS) assay. HCT116 cells, which possess a defect in ATM
signaling to Cisplatin (see, Kim et al.; Oncogene 21:3864 (2002);
see also, Takemura et al.; JBC 281:30814 (2006)) are plated at 470
cells per well in 96-well polystyrene plates (Costar 3596) in 150
.mu.l of McCoy's 5A media (Sigma M8403) supplemented with 10%
foetal bovine serum (JRH Biosciences 12003),
Penicillin/Streptomycin solution diluted 1:100 (Sigma P7539), and 2
mM L-glutamine (Sigma G7513), and allowed to adhere overnight at
37.degree. C. in 5% CO.sub.2. Compounds and Cisplatin are then both
added simultaneously to the cell media in 2-fold serial dilutions
from a top final concentration of 10 .mu.M as a full matrix of
concentrations in a final cell volume of 200 .mu.l, and the cells
are then incubated at 37.degree. C. in 5% CO.sub.2. After 96 h, 40
.mu.l of MTS reagent (Promega G358a) is added to each well and the
cells are incubated for 1 h at 37.degree. C. in 5% CO.sub.2.
Finally, absorbance is measured at 490 nm using a SpectraMax Plus
384 reader (Molecular Devices) and the concentration of compound
required to reduce the IC50 of Cisplatin alone by at least 3-fold
(to 1 decimal place) can be reported.
Example 5
Single Agent HCT 116 Activity
[0245] Compounds can be screened for single agent activity against
HCT116 colorectal cancer cells using a 96 h cell viability (MTS)
assay. HCT116 are plated at 470 cells per well in 96-well
polystyrene plates (Costar 3596) in 150 .mu.l of McCoy's 5A media
(Sigma M8403) supplemented with 10% foetal bovine serum (JRH
Biosciences 12003), Penicillin/Streptomycin solution diluted 1:100
(Sigma P7539), and 2 mM L-glutamine (Sigma G7513), and allowed to
adhere overnight at 37.degree. C. in 5% CO.sub.2. Compounds are
then added to the cell media in 2-fold serial dilutions from a top
final concentration of 10 .mu.M as a full matrix of concentrations
in a final cell volume of 200 .mu.l, and the cells are then
incubated at 37.degree. C. in 5% CO.sub.2. After 96 h, 40 .mu.l of
MTS reagent (Promega G358a) is added to each well and the cells are
incubated for 1 h at 37.degree. C. in 5% CO.sub.2. Finally,
absorbance is measured at 490 nm using a SpectraMax Plus 384 reader
(Molecular Devices) and IC50 values can be calculated.
Example 6
Pharmacokinetics
[0246] Noncompartmental pharmacokinetic parameters are analyzed
using Watson Bioanalytical LIMS (Version 7.4; Thermo Fisher
Scientific) from either the blood or plasma samples. The following
parameters are estimated following intravenous (IV) dosing;
terminal elimination half-life (T.sub.1/2=ln(2)/.lamda.z, where
.lamda.z is the first order rate constant associated with the
terminal (log-linear) portion of the curve.
[0247] The area under the curve (AUC.sub.last=area under the curve
from the time of dosing to the last measurable concentration). The
area under the curve extrapolates to infinity
(AUC.sub.0-.infin.=AUC.sub.last+C.sub.last/.lamda.z). The clearance
(Cl; Cl=Dose.sub.IV/AUC.sub.0-.infin.). The area under the first
moment curve (AUMC.sub.last=area under the concentration times time
versus time curve from the time of dosing to the last measurable
concentration). The area under the first moment curve extrapolates
to infinity
(AUMC.sub.0-.infin.=AUMC.sub.last+C.sub.last.times.t/.lamda.z+C.sub.last/-
.lamda.z.sup.2). The mean residence time
(MRT=AUMC.sub.0-.infin./AUC.sub.0-.infin.) and the steady state
volume of distribution (Vdss=MRT.times.Cl).
[0248] Clearance and volume of distribution can also be obtained
using methods known to one of skill in the art (see e.g., Handbook
of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism
for Industrial Scientists, Younggil Kwon, pp 18-28
(Non-compartmental Approach)).
Example 7
Clonogenic Cell Survival Assay
[0249] Compounds can be tested in a clonogenic cell survival assay
under conditions known to one of skill in the art to evaluate the
effectiveness of various combination therapies on cancer cells.
[0250] ATR inhibitors VE-821 and VE-822 were tested in a clonogenic
cell survival assay with irradiation (ionizing radiation) alone and
also in combination with ABT-888, a potent PARP1 and PARP2
inhibitor. Clonogenic survival of cancer cells from RKO and
MDA-MB-231 cancer cell lines were evaluated and results are shown
in FIGS. 1, 2, and 3.
Example 8
Cancer-Selective Synergistic Effects of VE-822 with Rucaparib
[0251] FIG. 4. H23 non-small cell lung cancer (a), U2OS
osteosarcoma (b), HCT116 colorectal cancer (c), MCF7 breast cancer
(d), HT144 melanoma (e), HT29 colorectal cancer (f) and PSN1
pancreatic cancer (g) cells were treated in triplicate with the
indicated concentrations of VE-822 and Rucaparib for 96 h, cell
density was measured by
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
-2H-tetrazolium (MTS) assay and synergy was analyzed at the 95%
confidence interval with MacSynergy II software. A range of synergy
was observed from strong (a) to negligible (g). The synergy plots
can be analyzed using methods described in Reaper et al, "Selective
Killing of ATM- or p53-deficient cancer cells through inhibition of
ATR", Nat. Chem. Bio. 2011, Apr. 13; 9 (7):428-430. The data
demonstrates that VE-822 synergizes with the PARP inhibitor
Rucaparib in many (but not all) cancer cell lines in vitro.
Example 9
Synergistic Effects of VE-822 with Rucaparib in Cancer and
Non-Cancer Cells
[0252] FIG. 5. H23 non-small cell lung cancer (a) and HFL1 normal
lung (b) cells were treated in triplicate with the indicated
concentrations of VE-822 and Rucaparib for 96 h, cell density was
measured by
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
-2H-tetrazolium (MTS) assay and synergy was analyzed at the 95%
confidence interval with MacSynergy II software. The synergy plots
can be analyzed using methods described in Reaper et al, "Selective
Killing of ATM- or p53-deficient cancer cells through inhibition of
ATR", Nat. Chem. Bio. 2011, Apr. 13; 9 (7):428-430. The data
demonstrates that VE-822 synergizes with the PARP inhibitor
Rucaparib in cancer but not normal cells in vitro.
Example 10
Synergistic Effects of VE-822 with Rucaparib and Ionizing
Radiation
[0253] FIG. 6a. H23 non-small cell lung cancer (a) and HFL1 normal
lung (b) cells were treated in triplicate with the indicated
concentrations of VE-822 and Rucaparib together with 2 gray (Gy) of
IR, cell density was measured after 96 h by
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
-2H-tetrazolium (MTS) assay and synergy was analyzed at the 95%
confidence interval with MacSynergy II software modified for triple
combination studies (Nguyen et al, PLOS One 5:9332). The synergy
plots can be analyzed using methods described in Reaper et al,
"Selective Killing of ATM- or p53-deficient cancer cells through
inhibition of ATR", Nat. Chem. Bio. 2011, Apr. 13; 9 (7):428-430.
The data demonstrates that cancer-selective synergistic effects for
the combination of VE-822, the PARP inhibitor Rucaparib and
Ionizing radiation (IR).
Example 11
Synergistic Effects of VE-822 with Rucaparib and Cisplatin
[0254] FIG. 6b. H23 non-small cell lung cancer (a) and HFL1 normal
lung (b) cells were treated in triplicate with the indicated
concentrations of VE-822 and Rucaparib together with 80 nM
cisplatin, cell density was measured after 96 h by
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
-2H-tetrazolium (MTS) assay and synergy was analyzed at the 95%
confidence interval with MacSynergy II software modified for triple
combination studies (Nguyen et al, PLOS One 5:9332). The synergy
plots can be analyzed using methods described in Reaper et al,
"Selective Killing of ATM- or p53-deficient cancer cells through
inhibition of ATR", Nat. Chem. Bio. 2011, Apr. 13; 9 (7):428-430.
The data demonstrates that cancer-selective synergistic effects for
the combination of VE-822, the PARP inhibitor Rucaparib and
cisplatin.
[0255] While we have described a number of embodiments of this
invention, it is apparent that our basic examples may be altered to
provide other embodiments that utilize the compounds, methods, and
processes of this invention. Therefore, it will be appreciated that
the scope of this invention is to be defined by the appended claims
rather than by the specific embodiments that have been represented
by way of example herein.
* * * * *
References